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Summary
The balance between matrix metalloproteinases (IvflVIPs) and tissue inhibitors of
metalloproteinases (TEvIPs) is very important in the normal turn over and
integrity of the cartilage extracellular matrix. In diseases such as rheumatoid
arthritis and osteoarthritis, this balance is altered in favour of MMPs leading to
the destruction of cartilage matrix. In cartilage, TIMPs are produced by
chondrocytes and are specific inhibitors of MMPs. The balance between TllvIPs
and MMPs is regulated by cytokines and growth factors. Transforming growth
factor beta (TGf-) induces TIMP-3 in chondrocytes and promotes matrix
synthesis. In this study, we have studied different mechanisms involved in TGF
13-induced TIMP-3 gene expression in chondrocytes.
1) In the first study, we have demonstrated the role of extracellular-signal
regulated kinase (ERK)-mitogen-activated protein kinases (MAPK) in TGF
beta-induced TIMP-3 gene expression in chondrocytes and chondrosarcoma
ceils. TGF-3 time-dependently induced phosphorylation of ERK-MAPKs in
primary human or bovine chondrocytes. PD98059 and U0126, specific inhibitors
of this pathway downregulated the TGF-f3-induced expression of TIMP-3 RNA
and protein. Additionally, we have investigated the role of Spi which is a down
stream target of ERK by using mithramycin and WP63 I which inhibited the
binding of Spi to its consensus site resulting in the decreased expression of
TIMP-3. Transfection of cytomegalovirus (CMV) promoter-Spi plasmid
increased human TIIVIP-3 promoter (-940 to +376)-driven luciferase activity.
Transfection of an antisense phosphorothioate oligonucleotide for Spi
suppressed TGf-beta-induced TIIvIP-3 protein expression while sense control
had no effect.These resuits show the involvement of ERK-MAPK pathway and
Spi transcription factor in the induction of THvIP-3 by TGF-beta in
chondrocytes.
2) In the second study, we have investigated the role of AKT/protein kinase B
signaling pathway for TGF-f3-induced expression of TIMP-3 in human articular
chondrocytes. TGf-3 stimulated the phosphorylation of AKT in a delayed and
sustained fashion which correlated with TIMP-3 mRNA induction.
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Phosphatidylinositol kinase (PI3K) inbibitors, Wortmannin, LY294002 and AKT
inhibitor (NL-7 1-101) significantly inhibited TGF-13-induced AKT
phosphorylation and TflvIP-3 expression. PI3K, AKT and Spi small interfering
RNA (siRNA)-mediated knockdown of target genes significantly reduced the
expression of TGF-13-induced expression of TIMP-3. Wortmannin, LY294002,
NL-71-101 and siRNA specific for AKT also inhibited the binding of
transcription factor Spi and TIIvIP-3 promoter (-940 to +376)-driven luciferase
activity. TGF-fl induced phosphorylation of p70S6 Kinase ami TEvIP-3 protein
induction, which was inhibited by rapamycin. The study shows the partial
involvement of PI3KJAKT pathway and Spi transcription factor. Furthermore,
TGF-$-induced TJMP-3 gene expression is regulated by a transiational
mechanism involving mammalian target of rapamycin (mTOR) signaling. TGF-13-
induced pro-survival AKT and ERK cascades and TIIvIP-3 expression can be
related to strengthening and maintenence of cartilage extracellular matrix and
joint tissue integrity.
3) Finally, the role of Smad pathway in TEvIP-3 regulation was investigated.
TGF-j3 stimulated the phosphorylation of Smad2 and TIMP-3 protein expression,
which is inhibited by the Smad2 inhibitors, PD1 69316 and SB203580 and flot by
their inactive analogue SB202474. The inhibitor of Smad3, SIS-3 and Smad2,
Smad3, Smad4 small interfering RNA mediated knockdown of target genes
significantly reduced the expression of TGF-3-induced expression of TIMP-3.
Transfection of the Smad2 and Smad3 small interfering RNA also inhibited the
TIMP-3 promoter (-940 to +376)-driven luciferase activity. Deletion and
transfection analysis of TIMP-3 promotor revealed that most of the TGF-3
responsive elements were present within the —167 base pairs with respect to the
transcription start site. Chromatin Immunoprecipitation (ChIP) analysis
confirmed binding of Smad2 and Smad4 with the —940 and —333, whereas Spi
binds with the —940, -333 and -i67 promoter sequences.
Overail this research showed that ERK, AKT and Smad pathways are involved
in TGF-f3-induced expression of TllvfP-3 in chondrocytes and together are
Iv
responsible for maintenance, strengthening and promotion of cartilage
extracellular matrix synthesis.
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Résumé
L’équilibre entre les métalloprotéinases de la matrice (MMPs) et les inhibiteurs
tissulaires des métalloprotéinase (TllvlPs) est très important pour l’entretien et
l’intégrité de la matrice extracellulaire du cartilage. Dans les maladies, telles que
l’arthrite rhumatoïde et l’ostéoarthrite, cet équilibre est altéré en faveur des MMPs,
menant à la destruction de la matrice du cartilage. Dans le cartilage, les TIMPs sont
produits par les chondrocytes; ils sont les inhibiteurs spécifiques des MMPs.
L’équilibre entre les TINPs et les IvIMPs est régie par les cytokines et les facteurs
de croissance. Le facteur de croissance transformant TGF-t3 induit le TINP-3 dans
les chondrocytes et favorise la synthèse de la matrice. Dans cette étude, nous avons
examiné différents mécanismes impliqués dans l’induction de l’expression du gène
TIIvIP-3 par TGF-t3, dans les chondrocytes.
1) Dans la première étude, nous avons démontré les rôles d’ERX (extracellular
signal-regulated-kinase), un des MAPK (mitogen-activated-proteine-kinases) dans
l’expression du gène TIMP-3, induite par TGF-j3, dans les chondrocytes humains.
L’induction de la phosphorylation d’ERK-MAPKs par TGF-t3, dans les
chondrocytes primaires humains ou bovins, est dépendante du temps d’incubation.
Les inhibiteurs spécifiques de cette voie, le PD98059 ainsi que le U0126 diminuent
l’expression de la protéine et de l’ARN de TIMP-3. Nous avons également
examiné le rôle de Spi, cible en aval d’ERK, en utilisant les inhibiteurs mitramycine
et WP 631. Ces deux produits empêchent la liaison de Spi à son site de consensus et
il en résulte une diminution dans l’expression de TIMP-3. La transfection du
promoteur de cytomegalovims (CMV), attaché avec le gène Spi, a augmenté
l’activité de la luciférase régulée par le fragment promoteur de TlivIP-3 (-940 à
+376). La transfection d’un oligonucleotide antisense phosphorothioate pour Spi a
supprimé l’expression de la protéine de TJMP-3 induite par TGF-3, alors que le
contrôle” sense” n’avait aucun effet. Ces résultats montrent l’implication de la voie
ERK-MAPK et celle du facteur de transcription Spi dans l’induction de TTMP-3 par
TGF-i3, dans les chondrocytes.
2) Dans la deuxième étude, nous avons examiné le rôle de la voie de signalisation
d’AKT/protéine kinase B dans l’expression de TIMP-3 induite par TGF-j3, dans les
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chondrocytes articulaires. Le TGF-3 a stimulé la phosphorylation d’AKT d’une
manière soutenue et retardée, en corrélation avec l’induction d’ARNm de IIMP-3.
Les inhibiteurs de phosphatidylinositol kinase (P 13K), Wortmannin, LY294002 et
l’inhibiteur d’AKT, le NL-71-i0i, suppriment d’une manière significative la
phosphorylation d’AKT, ainsi que l’expression de TIMP-3 induite par TGF-.
L’ARNsi contre P 13K, AKT et Spi réduisent d’une manière significative
l’expression de TEvIP-3, induite par TGF-béta. Wortmannin, LY294002, NI-71-101
et AKT ont également supprimé la liaison du facteur de transcription Spi et
l’activité de la luciférase actionnée par le promoteur de TIIvIP-3 (-940 à +376). La
phosphorylation de p7056 et de TIMP-3 induite par TGF-(3, a été inhibée par le
rapamycin. L’étude montre l’implication partielle de la voie de P13K /AKT ainsi
que celle du facteur de transcription Spi. De plus, l’expression du gène TflvIP-3
induite par TGF-t3 est contrôlée par un mécanisme traductionnel impliquant le cible
mammifere de rampamycine (TORm). Les cascades pro-survie AKI et ERK
induites par TGF-3, peuvent se lier pour renforcer et maintenir l’intégrité de la
matrice extracellulaire du cartilage ainsi que celle du tissu de l’articulation.
3) Finalement, nous avons étudié le rôle de la voie de SMAD dans la régulation de
TIMP-3. TGF-f3 stimule la phosphorylation de SMAD2 et de la protéine TIIVIP-3,
qui sont inhibées par les inhibiteurs de SMAD2, (PD169316 et $B203580) et non
par leur analogue inactif, le SB202474. L’inhibiteur de SMAD3, le SIS-3 et
l’inhibition des SMAD2, SMAD3, SMAD4 par ARNsi, réduisent d’une manière
significative l’expression de TIIvIP-3 induite par TGF-3. La transfection d’ARNsi de
SMAD2 et de SMAD3 a également inhibé l’activité de la luciférase actionnée par le
promoteur de TIMP-3 (-940 à +376). La transfection des mutants du promoteur de
TIIvIP-3 a révélé que la plupart des éléments réagissant à l’action de TGF-j3 étaient
présents dans les paires de base -167, en tenant compte du début du site de
transfection. Une analyse de l’immunoprécipitation de la chromatine (ChIP) a
confirmé la liaison de $mad2 et $mad4 avec les séquences -940 et -333, et de Spi
avec les séquences -940, -333 et -167 due promoteur.
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Dans l’ensemble, ces recherches ont démontré que les voies d’ERK, d’AKT et de
SMAD sont impliquées dans l’expression de flMP-3 induite par TGF-f3 et ce, dans
les chondrocytes Ensemble, ils sont responsables pour l’entretien, la fortification et
la promotion du synthèse de la matrice extracellulaire du cartilage.
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1. Introduction
1.1 Facts about arthritis in Canada
According to Canadian health statistics (1)
• Approximately four million Canadian adults over the age of 15 years have
arthritis. Two-third ofthem are women.
• Three out of five people with the disease are ofworking age (under 65).
• In comparison with the people having other chronic conditions, people with
arthritis experiences moderate to severe pain, restricted activity in their
daily life and long-term disabiiity. These peopie suffer from sleep disorders
and depression, and frequently visit the health care professionals.
• Musculoskeletal disorders including arthritis cost 16.4 billion dollars in
Canada.
• The estimated cost of arthritis is 4.4 billion dollars annually.
• Long-term disability accounts for 80 per cent of arthritis-related costs and
70 per cent ofthese costs is for the individuals between the ages of 35-64.
• The musculoskeletal disorders accounted for 10.3 per cent of the total
economic burden of ail iilnesses, but receive only 1.3 per cent of health
science research funding.
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1.2 Osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis and affects 10% of the
population especially the elderly. OA generally leads to disabilities due to its
common occurence in hee and bip joints. It limits the daily activity of the patient
and is a major cause of hip replacement surgeiy. OA is influenced by many factors
such as gender and genetic factors including inherited disorders of type II collagen
(COL2A1) mutations and ethnicity; non-genetic factors are, aging, obesity,
depletion of sex hormones in fernale and previous surgery. Environmental factors
include the nature of daily work, leisure and sports activities (2). In OA the whole
joint is involved in the disease and there is a graduai loss of the cartilage, bone
undemeath the cartilage, osteophyte formation, increased thickness of the
subchondral bone and bridging muscle around the joint becomes weak. The
synovium become relatively thick with an increase number of lining celis and an
infiltrate of macrophages. Proinflamatoiy cytokines such as IL-113 and TNF-Œ
secreted by the synovial macrophages are the key factors responsible for OA. IL-
113 and TNf-a affects the other matrix degrading enzymes, such as
metalloproteinases 1 and 3 produced by synovial fibroblast cells (3). Other
cytokines like IL-17 and IL- 1$ are also responsible for the induction of MMP-3
and inducible nitric oxide synthase (iNOS) in chondrocytes (4,5). The cytokines
and metalloproteinase alter the metabolism in such a way that leads to the
destruction of cartilage and joints.
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1.3 Rheumatoid arthritis
Rheumatoid arthritis (RA) is common throughout the world and approximately 1%
of the population suffers from RA. RA is an autoimmune disease of synovial
joints, with chronic inflammation leading to the destruction of cartilage and bone.
RA risk is associated with major histocompatibility complex class II. Type II
collagen and human cartilage glycoprotein 39 (HC-gp39) are the target proteins of
autoimmunity (6). RA is charactenzed by the excessive growth of synovial
membrane leading to the formation of pannus tissue and increased infilteration of
inflammatory ceils. Cytokines, growth factors, chemokines and metalloproteinases
are involved in the development of disease (7). T ceils play an important role in the
inflammation of RA. The activated T celi can induce IL-1, TNF-a and
metalloproteinases, which are responsible for the degradation of collagen and
proteoglycan in extracellular matrix (6).
The potential targets for therapies are TNF-Œ and IL-1. A number of anti-TNF-Œ
drugs are available in the market. The most important dmgs, which are in use in
US and Europe for RA treatment, are TNF-a antibody (infliximab RemicadeTM)
and TNF-receptor-immunoglobulin fusion protein (etanercept, EnbrelTM). These
inhibitors relieve symptoms of pain and swelling of joints (8). A new drug
Arcoxia, a chemical relative of Vioxx from Merck & Co is available in the market.
Nonsteroidal anti-inflammatory dmgs (NSADS) like cyclooxygenase-2-specific
(COX-2) inhibitors block an enzyme cyclooxygenase that is involved in
prostaglandin synthesis leading to arthritic pain. Celebrex is another COX-2
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inhibitor available in market. Some of these inhibitors have cardiovascular side
effects. Merck has withdrawn Vioxx from the market voluntarily due to daim by
the people that their loved ones have suffered from heart attack due to the use of
Vioxx.
1.4 Chondrocytes and their functions
Chondroblasts and chondrocytes originate from mesenchymal chondroprogenitor
ceils during the development of embryo. Morphologically, these ceils are spindie
shaped, having large, spherical nuclei and small arnount of cytoplasm. The
mesenchymal celis have the potential to develop into cartilage both in vivo (9) and
in ceil culture (10), and with advancing cellular aggregation start to show the
presence of cartilage transcription factor, Sox9, which is a marker of chondrocytes.
Type II collagen mRNA level also increases and the level of mRNA of the core
protein ofproteoglycan also becomes detectable (11).
Chondrocytes represent the celi type present in the hyaline cartilage. They are
responsible for the synthesis of extracellular matrix during development and
growth and maintain tissue homeostasis. They produce cytokines, growth factors
and proteases, which are responsible for the normal turnover of the tissue. An
upset in the balance of these factors, particularly an increase in proteinases results
in complications and development of arthritis (4).
4
1.5 Extracellular Matrix (ECM)
The extracellular matrix is composed of 65 to 80% water. Water content is
maximum in superficial zone and decreases progressively with increase in depth.
Collagen II accounts for 15 to 25% ofthe wet weight and about halfthe dry weight
except in the superficial zone where it accounts for most of the dry weight and its
concentration is progressively reduced with increasing depth from the articular
surface. The proteoglycan aggrecan content constitute up to 30% of the dry weight
of proteins. Aggrecan degradation products, which accumulate with age consist
mainly of the Gi globular domain and Gi, G2 along with keratan sulfate-rich
region account for a significant part of the remaining dry weight (12). The fibrous
structure is mainly composed of type II collagen made up of tropocollagen
molecules having a triple lieux of three identical a chains, with non-helical amino
and carboxyl-terminal domains. These collagen molecules are linked through
hydroxypyridinium cross-links (13). These cross-links strengthen the collagen and
render it more resistant to proteolysis. The turnover of collagen in healthy human
articular cartilage is probably very low as it has the halfiife ofover 100 years (14).
However in pericellular region there is some evidence for ongoing type II collagen
cleavage (15). Type IX collagen is bound with type II collagen by cross-linking
with its N-terminal and C-terminal nonhelical domain in an antiparallel manner
(16,17) and distributed periodically at a distance of 67nm. Its N-terminal globular
NC4 domain extends out of the fibril and is basic in nature, so it might act as a
binding site for glycosaminoglycans such as hyaluronic acid and chondroitin
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sulfate. Type XI is also found within type II collagen and restrict the lateral growth
of type II collagen fibrils (18). Type VI collagen is a shorter chain collagen that
consist of cx chains having no cross-links with other matrix molecules. They form
filamentous network in connective tissues. Type VI coïlagen is found throughout
the cartilage mati-ix but mainly present in pericellular matrix. (19). Type XII and
Xlv collagens are structurally similar to type DC collagen and are found in skin
and cartilage. Type XII is involved in early chondrocytes development (20).
The proteoglycan is another important structure of cartilage extracellular matrix
and binds to hyaluronic acid and is known as aggrecan. The core protein of
aggrecan consists of three globular domains, Gi, G2 and G3, and the region
between G2 and G3 is attributed for the glycosaminoglycan attachruent. Aggrecan
binds to the hyaluronic acid through its N-terminal Gi globular domain. The
function of G2 domain is not clear. The link protein binds directly to the Gi
domain of aggrecan and to hyaluronan and stabilizes the binding between aggrecan
and hyaluronan. The region adjacent to the G2 domain towards the G3 domain
contains 30 keratan sulfate chains. Each disaccharide contains at least one sulfate
group. Afier this is the chondroitin sulfate attachment region, and approximately
100 chondroitin sulfate chains are present in this region. Each disaccharide of
chondroitin sulfate contains both carboxyl and sulfate groups. So aggrecans are
highly negatively charged and are responsible for the high degree of hydration of
proteoglycan. The ability of hydration and swelling is restricted by the collagen
fibrillar network, which leads to the development of swelling pressure which
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contributes to its compressive stifffiess and ability to resist deformation under
mechanical load (21, 12). The C-terminal G3 domain prevents the core protein
from degradation and is responsible for processing and interacellular trafficking of
the protein (22).
Apart from this, there are lot of other molecules such as versican, structurally
similar to aggrecan and present at a low level in the interten-itorial region (23).
Decorin, biglycan and fibromodulin are smaller proteoglycans with fewer
glycosaminoglycan side chains, and are thought to play some role in the
organization of mati-ix. There are also some noncollagenous proteins with a
smaller amount of oligosaccharides, such as anchorin CII, cartilage oligomeric
protein, fibronectin and tenascin, ail these molecules play role in stabilizing matrix
and chondrocytes-matnx interaction (24). Remodeling ofthe cartilage ECM during
health and disease conditions takes place by a family of enzymes to be discussed in
the next section.
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1.6 Matrix metalloproteinases (MMPs), aggrecanases and TACE
The matrix metalloproteinases consist of a large family of proteolytic enzymes and
their over activity plays an important role in tissue destruction in RA, QA and in
many other diseases (25). They are produced in inactive proenzyme form, in which
the N-terminal cysteine residue binds with the Zn atom in the active site. The
removal of a 10 kDa N-terminal fragment leads to the activation of enzyme (26).
Some active MMPs are also responsible for the activation of other Pro-MMPs,
suggesting a carefully controlled activation cascade in vivo involving different
members of the MMP farnily. The membrane-type MMPs have a conserved
sequence of I O-20 amino acids between the propeptide and the N-terminal domain
recognized by the furin family of serine proteinases (27). These enzymes are
activated within the Golgi apparatus and arrive at the ceil surface in an active form
and are thought to be responsible for the activation of other MMPs. MTI -MMP
and MT2-MMP activate proteolytically proMMP-2 at the celi surface (2$).
Plasmin also activates sorne Pro-MMPs (29). Other mechanisms may involve the
activation of Pro-MMPs by reactive oxygen species released from inflammatory
cells (30).
Many types of cells, such as chondrocytes, synovial celis and polymorphonuclear
leukocytes, produce MMPs. Their synthesis is influenced by many factors such as
cytokines, growth factors, cellular transformation and physical stimuli (31). Some
of the MMPs take active part in the degradation of aggrecan and collagen in
cartilage. Collagenases (MMP-l, MMP-8 and MMP-13), gelatinase A (MMP-2)
$
and gelatinase B (MMP-9), stromelysin 1 (MMP-3), matrilysin 1 (MMP-7) and
membrane-type MT1-MMP (MMP-14) are found in cartilage and showed elevated
levels in the synovium and in the cartilage from patients suffering from RA and
OA (32, 33). Ail of these MMPs cleave the aggrecan core protein at various sites,
but the critical site is the Asn34 1—Phe342 bond located in the intergiobular domain
located between the two globular domains Gi and G2, resulting in the release of
aggrecan molecules from the cartilage (34). On the other hand, Sandy et al. (35)
reported the cleavage of core protein at the G1u373—A1a374 bond instead of
Asn341—Phe342 bond, when bovine cartilage explants in culture were treated with
IL-1. The products resulting from tins cleavage accumulate in ffie synovial fluids
of patients with OA (36). The enzymes responsible for tins cleavage have been
purified and cloned. They are referred to as aggrecanase 1 and aggrecanase 2 (also
ADAMTS-4 and ADAMTS-5, members of the ADAM protein family,
respectively) (37, 38). The degradation of type II collagen occurs siower than
aggrecan degradations in arthritis. Tins is ail due to the action of MMPs. Potential
collagenolytic enzymes are MMP-1, MMP-2, MMP-8, MMP-13 and MMP-14.
Some MMPs also act on non-matrix proteins substrate resulting in their activation,
such as the activation of insulin-like growth factor-binding protein (39), cleavage
of the Fas ligand by MMP-7 resulting in soluble Fas important in apoptosis (40)
and cleavage of laminin-5 by MT1-MIVIP resulting in the migration of variety of
cells (41). MMP activity also regulates ccli attachment and migration by cleaving
celi-ceil and celi-matrix receptors. Examples are the cleavage of 4 integnn by
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MMP-7 (42) and removal of E-cadherin by MMPs (43). TNF-alpha converting
enzyme (TACE) is responsible for the proteolytic activation of YNF-Œ (44), which
inhibits the synthesis of link protein and type II coliagen, and is a major factor
responsibie for the onset of arthritis (45).
1.7 Tissue inhibitors of metalloproteinases (TIMPs) and arthritis
MMPs can be inhibited by tissue inhibitors of metalloproteinases, which bind to ail
known active MMPs with a 1:1 stoichiometry. Ail connective tissues produce
members of the TIMP famlly (46) and these molecules play an important role in
controlling connective tissue breakdown by blocking the action of active MMPs.
Four members of the TIMP family have been described and these share similar
secondary and tertiary structures. and are able to inhibit MMPs, aithougli with
different potencies. Dean et al (47) reported higher levels of TIMP and MMP in
OA cartiiage. Aithough the level of MMP was oniy slightly higher as compared to
TIMP in normai cartilage, this difference in ratio is responsible for the cartilage
matrix degradation. TIMPs consist of a N-terminal inhibitoiy domain and a C-
terminal reguiatoiy domain. TIMPs blocks MMP activities by interacting with the
zinc-binding region in the catalytic dornain of MMPs.
TIMP- 1 is produced in response to a variety of extemal stimuli, such as growth
factors and cytokines, whereas expression of TIMP-2 is mostly constitutive (48).
TIMP-1 inhibits aggrecanase-1 (49) and MMPs, and inhibitoiy activity resides
between the cysteine-3 and cysteine-13 in the N-terminal domain (50). The TIMP
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1 level was reported higher in synovial fluids (51) and in serum (52, 53) of RA
patients, but not in the sera of OA patients (54). TIMP-1 overexpression by
adenovirus-based gene delivery reduced destruction of the joints of TNF-a
transgenic mice (55). On the other hand the overexpression of TIMP-1 did not
prevent osteochondral injury in the mouse model ofcollagen-induced arthritis (56).
TLN4P-2 interaction with MMP-2 is strong as compared to MMP-9. The C-terminal
domain of TIMP-2 binds with the C-terminal domain of progelatinase A
(proMMP-2) on celi surface to activate proMMP-2 by membrane-bound
membrane type 1 matrix metalloproteinase (MT 1 -MIVIP) (57). TIIvIP-3 is different
from other TIIVIPs in many ways. TIMP-1 and TIIvIP-2 are in soluble forms, where
as TIMP-3 is secreted and binds to the ECM. TTMP-3 protein binds to the ECM
components, heparan suiphate and chondroitin sulphate through the N-terminal
domain of human TIIvIP-3 nch in lysine and arginine (5$). Mutations in the TIMP
3 gene are implicated in a human disease called Sorby’s fundus dystrophy, a
degenerative eye disease (59). TIMP-3 lias also shown proapoptotic role in both
normal and cancer ceil unes (60, 61). T1MP-3-deflcient mice developed alveolar
air space enlargement resulting in impaired capacity for gas exchange (62),
increased mammary gland apoptosis (63), abnormal cardiac function (64), and
increased susceptibility to hepatic inflammation (65). TIMP-3 knockout mice have
shown increased aggrecan and collagen degradation with aging, in a manner
similar to OA (66).
11
The above findings suggest that TIMP-3 plays an important roles in physiological
and pathological processes. The speciai characteristics of TIMP-3 invite focus of
studies in its biological role. TIMP-3 is known to inhibits MMP-3, collagenase-3,
tumor necrosis factor-a converting enzyme (ADAM-17), aggrecanase-1
(ADAMTS-4) and aggrecanase-2 (ADAMTS-5) in vivo. This is also based on
experiments where TIMP-3 nuli mice have shown increased inflammatory
response on intra-articular injection of methylated bovine serum aibumin as
compared to wild type mice (67). The loss of aggrecan is the initiai and key step in
the pathogenesis of arthritis (68). Therefore, TIIvIP-3 might play a key preventive
role in arthritis development.
1.8 Growth factors and Arthrïtïs
Cytokines and growth factors can be divided into two groups, anti-inflammatory
and pro-inflammatory, exerting anabolic or catabolic effects respectively on
cartilage in arthritis. The cytokines and growth factors that affect the matrix
synthesis and degradation are shown in Figure A. The growth factors oppose the
effects of the pro-inflammatory counterparts and promote the synthesis of matrix
and repair, induce the protective enzyme inhibitors such as TIMPs, down regulate
the destructive enzymes and reduce the levels ofpro-inftammatory cytokines (69).
TGF-i3 is weil-known for its chondroprotective effects and for its role in the
promotion of matrix synthesis. Cartilage contains vast stores of TGf-j3, up to 300—
500 ng /g of cartilage mass, which is mostly inactive and requires proteolytic
activation. The presence of such reserves strongly indicates the role of TGF-$ in
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cartilage metabolism (70). There are three isoforms ofTGf-3 (TGF- 1, 2, and 3)
in mammals, ail of them are expressed in articular chondrocytes, (71) as weli as in
other ceils. Basic fibroblast growth factor (bFGF) also stimulates the production of
TGF3 (72). TGFÇ3 and bFGF exhibit synergism, resulting in up to a 73-fold
increase in chondrocyte replication (73). TGF-13 stimulates differentiation of
mesenchymal stem celis to chondrogenic phenotype in vitro, and these ceils start to
express type II collagen, aggrecan, fibromodulin and cartilage oligomeric protein
(74). TGF-f3 counteracts the effects of IL-1-mediated destructive effects in
chondrocytes in vitro (75), and in mice with induced inflammatory arthritis (76).
This effect may be due to its ability to inhibit IL-1 receptor expression (77). The
transgenic mice with blocked TGF- signal, either due to inactive TGF-f3 type II
receptor (78) or due to interference in intraceliular signaling by Smad3 (79), has
shown the development of degenerative joint disease similar to OA in humans.
These observations suggest that impaired TGF-3 function could be a possible
cause of OA. On the other hand, it has aiso been reported that TGF-13 induces more
PG synthesis in human OA cartilage as compared to normal cartilage in vitro (80).
TGF-î3 levels are relatively elevated in the synovial fluid of OA and rheumatoid
arthritis patients (81). Excessive injections of TGF-f3 into mouse knee joints leads
to the osteophytes formation on the articular surface and cartilage lesions due to
PG depletion as in OA ($2), winch indicates that excessive TGF-f3 activity is
responsible for some ofthe pathological changes in OA.
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Figure A. Cytokines and growth factors effecting cartilage matrix degradation or
syrithesis. TGF-f3, transforming growth factor beta; IGF-1, insulin like growth
factor 1; bFGF, basic fibroblast growth factor; PDGF, platelet-derived growth
factor; IL, interleukin; IL-1 Ra, interleuldn- 1 receptor antagonist; sTNF-R, soluble
tumor necrosjs factor-a receptor; TNF-cx, tumor necrosis factor-a OSM,
oncostatin M; , stimulatory effect, , inhibitory effect.
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IGF-1 play anabolic role in matrix production (83) and inhibits the activity of IL-1,
especially the degradation of proteoglycan by IL-1. The inhibition of IL-1 activity
by IGF-1 is of potential importance in decreasing cartilage degradation and the
progression of OA (84). IGF-1 and TGF-f3 have shown synergistic effect in
inducing type II collagen and aggrecan proteins in aduit articular chondrocytes
(85). IGf-I expression is significantly higher in OA cartilage (86), which also has
increased number of IGF receptors (87) even then the celis did not show full
response to exogenous IGF-I (88). The loss of IGF-1 activity and effects in OA
might be due to upregulation of IGF-binding proteins (IGFBPs) (89). IGf-1 is
sequestered from its ceil-surface receptor by IGFBPs and fibronectin, affecting the
bioavailability of IGF- 1. IGFBP-3 expression increases with advancing age and
affects mati-ix synthesis in inverse proportion. These proteins are also
overexpressed in OA cartilage and cause metabolic disturbances (90). The rats
deficient in pituitary growth hormone (GH) and IGf-1 has shown OA like lesions
as compared to the normal rats. The decrease of the level of the GH and IGF-l
with advancing age may be the contributory cause ofOA (91).
FGF-2 along with IGF-1 synergistically enhanced the proliferation of human
articular chondrocytes 7.5- fold in two weeks as compared to their individual effect
(92). FGF-2 has a very important role in modulating cartilage repair. In an intrinsic
damage-repair response in articular cartilage explant treated with FGF-2, the
repaired chondrocytes have shown increased expression of type II, DC, XI coïlagen
but flot type I coÏlagen (93). IGF-1, TGf-3, FGf-I, II, and platelet derived growth
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factor (PDGf) ail have shown to augment chondrocyte proliferation in vitro (94).
The intra-articular administration of bFGf in the form of gelatin hydrogel
increased the synthesis of ptoteoglycan core protein and had shown therapeutic
effect on OA in rabbit knee joint (95). However the higher concentration ofbFGF
inhibit the anabolic effect of IGF-1 by decreasing the proteoglycan synthesis in
chondrocytes (96). The synoviocytes of RA patient produced more acidic
fibroblast growth factor, which may be responsible for angiogenesis and fibroblast
proliferation (97).
The bone morphogenetic protein BMP farnily consists of 13 proteins and ail
belong to the TGf-3 superfamily except BMP-1 (98). BMPs promote
chondrogenesis. BMP-2 (99), BMP-3, BIVW-4 (100) and BMP-7 (101) stimulate
the PG synthesis in vitro in articular cartilage. BMP-7 also counters the effects of
the IL-1-induced dowuregulation of PG biosynthesis of articular chondrocytes in
vitro (102).
1.9 Cytokines and Arthritis
Proinftammatory cytokines include the TNFs, ILs, and colony-stimulating factors.
TNF-Œ and IL-l j3 are key cytoldnes responsible for the pathology of OA (103).
They also affect the activity of other cytokines, e.g., IL-6, IL-8, and leukemia
inhibitory factor (LIE), which are synthesized in increased amounts upon
stimulation of chondrocytes with TNf-Œ or IL-1f3 (104). IL-1f3 and TNF-Œ also
upregulate COX-2 expression in articular tissue, which is responsible for elevated
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prostaglandin E2 (PGE2) synthesis, responsible for inflammation in arthritis (105).
IL-1 is the important catabolic cytokine produced by the chondrocytes and its level
is upregulated in the synovial fluid of RA, OA and cartilage tissue (106). IL-1
upregulates matrix degrading enzymes, MMP-1, MMP-3, MMP-13 and
ADAMTS-4 and decreases the amount of mRNA for link protein in the articular
chondrocytes (107). IL-1 dowuregulates proteoglycans synthesis as well as type II
collagen (108). TNF-Œ also downregulates the synthesis ofproteoglycans and type
II collagen and shows synergistic effect with IL-1 on the inhibition of matrix
synthesis (109). IL-1 induced the production of nitric oxide (NO), which inhibits
proteoglycan synthesis and may be the primary mediator of inhibition of matrix
synthesis (110). IL-17 is a proinflamatory cytokine that increases the synthesis of
inducible nitric oxide synthase (iNOS), which is responsible for the generation of
NO causing cytotoxic response in RA. IL-18 induces MMP-1, MMP-3, MMP-13
and aggrecanase-2 in a monolayer culture of human articular chondrocytes and
seems to have some roles in degradation of cartilage in arthritis. IL-17 and TNF-a
exert synergistic effects in degrading cartilage and also inhibit the synthesis of
proteoglycan in vito. IL-17 and IL-18 induce IL-1f3, TNF-cL, MMP-3 and iNOS in
human articular chondrocytes (111,112,113).
The interaction of cytokines and their role in the metabolism of chondrocytes is
very complex. The exact roles of inflammatory cytokines other than IL-l I and
TNF-a in OA are flot very clear. Studies in animal models are under way to ffirther
reveal the pathogenesis of OA. Uptiil now, it is established that the cartilage
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destructive process in OA is mainly IL-1 driven, whereas TNF-cL is involved in the
onset of RA, and that direct generation of IL-1 may also occur in the complete
absence of TNF-a (114). OA cartilage shows strong intra- and extracellular
presence of IL-1f3 in the superficial zone by immunohistochemistry (115). The
biological activity of IL-1 3 in OA tissue is also increased due to an increase in the
number of IL-1 type 1 receptors on chondrocytes (116), decrease in the synthesis
of the natural receptor antagonist IL-iRa (117), and an increase in IL-1-
converting enzyme responsible forthe proteolytic activation ofIL-13 (118).
Interferon-y inhibits the synthesis of type II collagen (119), however the role of
interferon-y is dual. Interferon-y inhibits the IL-13-induced MMP-13 in
chondrocytes (120). Interferon-y also downregulates the expression of IL-17 and
confers resistance to collagen induced arthritis (CIA) in mice (121).
Cytokines like IL-4, IL-10, and IL-13 are classified as anti-inflammatory, because
they reduce the activity of the proinflammatory cytokines in vitro (122). IL-4
induces TIMP-1 and inhibits MMP-3 in human chondrocytes (123). It lias been
shown that IL-10 upregulates TIMP-1 while downregulates MMP-i and MMP-3 in
human monocytes (124). IL-13 reduces the production of MMP-1 stimulated by
IL-1 or IL-17 in cultured RA synoviocytes (125).
Recent studies indicate that some of the cytokines considered to be anti
inflammatory might not aiways be so. IL-6 cytokine family members, including
IL-6 and oncostatin M (O$M), induce TUVTP production in chondrocytes and
fibroblasts as well as increase matrix synthesis, and are considered as
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chondroprotective. However, in combination with IL-1, these cytokines induces a
marked catabolic effect by promoting matrix degradation (126). Our laboratory has
shown that OSM induces MMPs, aggrecanase and TIIvIP-3 (127,128). Overali, a
balance between proinftammatory and antiinflammatory cytokines is necessary for
maintaining cartilage integrity.
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1.10 IGF- Signaling
TGF- and reiated growth factors play a prominent role in the development,
homeostasis and repair of virtuaily ail tissues in organisms, from fruitfly to human.
Coiiectively, these factors account for a substantial portion of the intraceliular
signais goveming ceil fate. The first member of TGF-3 superfamily was
discovered 20 years ago. Since then the famiiy has grown, and it consists of over
thirty members of structuraily and functionaily related proteins (129).
TGf-r3 family signais via a transmembrane receptors complex that contains
intracellular serine-threonine kinase domains. This serine-threonine kinase
receptor complex consists of two different types of transmembrane proteins,
known as type I and type II receptors. The binding of TGF- to its receptor ieads
to the association of type I and type II receptors. Type II receptor then
phosphorylates type I receptor, leading to the activation of its kinase domain. Type
II receptors phosphoryiate themselves and type I receptors on serine and threonine
residues but not tyrosine residues (130). There are seven different types of type I
receptors, termed ALK1 -7 (activin receptor-like kinase) and five type II receptors
in mammalian ceils. TGF-13 generally uses ALK5 and TGF-fl type II receptor in
most of the celi types (131). There are also two additionai receptors, TGF-$ type
III and TGF-3 type V. TGF- type III receptor is a proteoglycan, also known as
betaglycan and acts as a co-receptor by presenting ligand to TGF-3 type II
receptor. The cytoplasmic domain of TGf-3 type III receptor binds with the
autophosphoryiated type II receptor and promotes the compiex formation between
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type II and type I receptors, and then dissociates from this activated signaling
complex. (132). TGF-f3 type V receptor, also known as low density lipoprotein
receptor-related protein-1 (LRP-1) and IGFBP-3 is a TGF-13 and IGFBP-3 receptor
and is involved in growth inhibitory response to TGF-f3 (133).
Glycosylphosphatidylinositol (GPI)- anchored proteins have been reported to
regulate TGf-3 signaling in certain ceil unes. These proteins can bind with the
TGF-3 type I and II receptors to form heteromeric complex. Mutant human
keratinocytes (HaCaT) celis deficient in GPI protein biosynthesis have shown
increased Smad2 and Smad3 activation in response to TGF-j3 treatment, and thus
GPI-anchored proteins are responsible for inhibiting TGF-3 signaling (134). A
variant of TGF-t3 type II receptor-B (TI3RII-B), which contains a 26-amino acids
insert instead of Va132 of the type II receptor, is expressed in normal and
osteoarthritic human chondrocytes. Tf3RII-B can combine with TGF-t3 type I, II,
betaglycan and endoglin leading to modulation of TGF-fl signaling.
Overexpression of TI3RII-B in chondrocytes has shown enhanced TGF-f3 responses
in chondrocytes (135).
Once the type I receptor is activated, it transmits signal to the SMADs which are
intracellular mediators. Type I receptor phosphorylates R-Smad on the serine
residues in the C-terminal region, Ser-Ser-X-Ser motif. Smad anchor for receptor
activation (SARA) and hepatocytes growth factor-regulated tyrosine kinase
substrate (HRS/HGS) both facilitate the phosphorylation of R-Smads by type I
receptor. These proteins contain the phospholipid binding FYVE domain, which
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helps in recruitment of Smad2 and Smad3 to the TGF-3 receptor complex.
Cytoplasmic promyelocytic leukaemia (cPML) is an adapter protein that promotes
ALK5 mediated R-Smad phosphorylation (136). Three of type I receptors are
responsible for the phosphorylation of R-Smads, Smad2 and $mad 3, and mediate
TGF-13-like signal, whereas other four receptors activate R-Smads, Smadl, Smad5
and Smad8 to transduce signais initiated by bone morphogenetic proteins. Upon
phosphorylation, these R-Smads dissociate from the receptor/SARA complex and
combine with Co-Smad, Smad4 to form a heteromeric complex and transiocate to
the nucleus. In the nucleus, this complex associates with one of various
transcriptional coactivators or corepressors, and interact with Smad binding
elements (SBE) or GC rich sequences in the promoter region of vanous genes,
thereby positively or negatively regulating gene expression. Direct binding of
Smads with DNA is very weak and their interaction depends on various DNA
binding proteins to target specific genes for transcription. TGF-13-regulated Smad2
and Smad3 directly bind to DNA-binding partners, such as FoxHi (FAST), AP-1,
TFE3, Spi, Mixer, Runx2, and Mizi, whereas the BMP-regulated Smads bind to
OAZ, Rumc2 and Hoxc-8/9. Afler binding to their target promoters, Smads can
regulate transcriptional activity positively or negatively by recruiting coactivators,
such as CBP/p300, or corepressors, such as TGIF and Ski/Sno (137). A schematic
diagram ofsmad signaling is shown in figure B.
In human skin fibroblasts, TGf-f3 induction of COL1A2 is mediated by Smad3
binding to the COL 1A2 promoter (138), whereas Smad3 and Smad4 are important
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Figure B. The transforming growth factor f3 (TGF-f3)/SMAD pathway.
Binding of TGF-f3 to the type II receptor brïng the type II receptor close to
type I receptor leading to the phosphorylation of type I receptor. The
activated type 1 receptor subsequently phosphorylates a receptor-regulated
SMAD (R-Smad) allowing this protein to associate with Smad4 and move
into the nucleus. In the nucleus, the SMAD complex associates with a DNA
binding partner, such as fast-l and this complex binds to specific enhancers
in targets genes activating transcription.
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in COL7A1 gene expression induced by TGf-13 in human dermal fibroblast (139).
The cooperation between Smads and Spi has been reported in the upregulation of
PAl-1 and COL1A2 in response to TGF-3 stimulation (140,141). In mammalian
epithelial ceils, Smads 2 and 3 mediate growth inhibition and transcriptional
activation ofTGF- and activin reporter genes (142,143).
Another class of Smads known as inhibitory Smads (I-Smads), Smad6 and Smad7
lack the C-terminal sites for phosphorylation by the type I receptor and antagonize
TGF-13 signaling. Smad6 and Smad7 negatively regulate the TGF-3 signaling via
distinct mechanisms. Smad6 inhibits only the BIvW pathway whereas Smad7
inhibits TGF-(3/activin and BMP pathways. Smad6 competes with Smad4 for
binding with phosphorylated Smadl forming Smadl/6 complex, which is unable to
regulate transcription (144). Smad7 competes with R-Smads and binds with type I
receptor (145). Smad7 binds with the Smurf2, a nuclear protein, and causes its
export and recruitment to the TGF-(3 receptor causing latter’s degradation (146).
In certain mammalian celis, the transfected TAK1 expression is increased on
stimulation with TGf- and BMP4. Overexpressing the kinase-defective TAK1
mutant (147) or the truncated form of the TAK1 activator, TAB 1, abolished the
TGF- response of a reporter gene construct that contains an AP-1 site, suggesting
the involvement ofTAK1 (148). TGF-3 activation ofthe MAP-kinase JNK, is also
involved in a similar transcriptional response and is downstream of TAK1 (149).
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However, the JNK-kinase response to TGF- is in a deiayed manner, indicating
that JNK is not a pnmary transducer ofTGF-13 signais in these ceils.
TGF-3 aiso signais through mitogen-activated protein kinases (MAPKs), which
transduce extemal signais into the ceil, resuiting in a wide range of celiular
responses, including growth, differentiation and deveiopment (150). There are
three different types of MAPKs. In our study, we have found the invoivement of
extraceliular signal-reguiated kinases (ERKs). ERK1 and ERK2 are isoforms and
coilectively referred to as ERK1/2. ERK1/2 are activated by MEK1/2, which are in
turn activated by MAPKKK mediated phosphorylation. MEKÏ/2 phosphorylates
threonine and tyrosine residues in the kinase domain of ERK1/2 leading to the
activation of ERK1/2. The activated ERK1/2 then phosphorylates many
transcription factors, such as C-Myc, Elkl and protein kinases resulting in the
induction ofmany genes (151). The detaii ofMAPKs pathways is given in section
1.11.
Phosphatidyiinositol 3-kinases (PI3K) pathway is also invoived in TGF-f3
signaling and plays important role in ceii physioiogy. PI3K pathway is activated
by the receptors tyrosine kinase and Ras, which in tum generates lipid second
messenger phosphatidyl inositol-3 ,4,5-triphosphate (Ptdlns(3 ,4,5)P3). The Ptdlns
(3,4,5)P3 phosphorylates AKT/PKB. The activated AKT phosphorylates
downstream a number of proteins resulting in the induction or repression of target
genes (158,159,160,161). The detail ofPI3Ks pathway is given in section 1.12.
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1.11 MAPK signaling
MAPKs are activated due to threonine and tyrosine phosphorylation within the
activation ioop of the kinase domain. MAPKs are activated by a family of dual
specificity kinases, known as MAPK kinases or MAPKJERK kinases
(MAP2Ks/MKKs or MEKs). MAP2Ks, in mm, are activated by Ser/Thr
phosphorylation catalyzed by any of several protein kinase families collectively
knowri as MAPK kinase kinases (MAP3Ks). So far, three major groups ofMÀPKs
have been foimd in mammals: the extracellular signal-regulated kinases (ERKs),
the c-Jun N-terminal kinases (mKs) and the p38 kinases. The JNKs and p38
kinases are also known as stress-activated protein kinases (SAPKs).
The ERKs are very important members within the MAPKs. They consist of
ERK1/2, ERK3/4 and ERK5/ BMK and new members, ERK7 and ERK8 (151,
152, 153). ERK1 and ERK2 are the best characterized ERKs and are co-ordinately
regulated. Dunng inflammation, the ERK1/2 pathway is triggerd by some cytokine
receptors, such as the interleukin-6 (IL-6) receptor, the T-cell receptor, and the B
ceil receptor. Enhanced ERK1/2 activity resuits in the activation of many
transcription factors, e.g., the activator protein-1 (AP-1) components, c-Fos and c
Jun (151, 154).
The JNK and p38 kinase pathways are activated by environmental stress and
inflammatory cytoldnes (155). The JNK family of MAPKs consists of JNK1 and
JNK2 that are expressed ubiquitously, and JNK3 is mainly expressed in the heart,
brain and testis (156). Inflammatory cytokines, such as TNF-a and IL-1, strongly
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activate JNKs (151). TNKs play a major role in many apoptotic processes and
mostly target transcription factors, such as AP-1 component c-Jun and activating
transcription factor-2 (ATF-2). The mammalian p38 family consists of four
isoforms, and can be activated by LPS, IL-1 and TNF-Œ (154, 157). The activation
of these pathways leads to increase or decrease in the expression of certain target
genes. The MAPK cascades are summarized in Figure C.
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Figure C. Mitogen-activated protein kinase (MAPK) signaling. Upon stimulation, a
kinase cascade is triggered that ultimately lead to gene expression. The three main
kinases are the MAPK kinase kinase (MAPKXK), MAPK kinase (MAPKK), and MAPK.
Abbreviations: CHOP, CREB homologous protein; G-protein, GTP-binding proteins;
ASK, apoptosis signal-regulating kinase; ERK, extracellular signal-regulated kinsae;
JNK, c-Jun N-terminal kinase; Max, Myc-associated factor X; MEK, MAPK!ERK
kinase; MEKK, MEK kinase; MKK, MÀPK kinase; MLK, mixed lineage kinase; Ras, rat
sarcoma virus; Rho, Ras homologous; Sapla, serum response factor accessory protein-la;
$APK, stress-activated protein kinase; TAK, transforming-growth-factor-3-activated
kinase.
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1.12 AKT signaling
In many cellular processes, phosphatidylinositol 3-kinases (PI3Ks) has a key
regulatory function. The PI3Ks are a family of enzymes that produce lipid second
messengers by phosphorylation of plasma membrane phosphoinositol. They are
heterodimeric proteins consisting of a catalytic subunit (110 kDa, p110) and an
adaptor/regulatory subunit p85. They are activated by G-protein-coupled receptors
(GPCRs) or receptors, which are tyrosine phosphorylated in response to
extracellular stimuli (158). Phosphatidylinoitol 3-kinases are also activated by
direct interaction with the small GTPase Ras (159,160). Upon activation, these
enzymes phosphorylate inositol lipids at various positions of the inositol ring to
generate the 3 -phosphoinositides, phosphatidylinositol 3-phosphate [Ptdlns (3) P],
phosphatidylinositol 3 ,4-bisphosphate [Ptdlns (3,4) P2] and phosphatidylinositol
3,4,5 -trisphosphate [Ptdlns (3,4,5) P3].
Phosphoinositides serve as binding targets for proteins containing pleckstnn
homology domains such as AKT/PKB (161). These phosphatidylinositol 3-kinase
lipid products bind to the pleckstrin-homology domain of Akt/PKB, while PDK1
and PDK2 are also recruited and activated. Subsequently, Akt/PKB is activated by
PDK1 and PDK2 through phosphorylation of the T308 and S473 residues of
Akt/PKB, respectively. The latter activated kinase phosphorylates several proteins
like S6 kinase (162), glycogen synthase kinase 3 (163) and forkhead-related
transcription factors that regulate the expression of p27Kip or cyclin Dl. The
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tumor suppressor protein PTEN negatively regulates phosphatidylinositol 3-kinase
lipid formation by its lipid phosphatase activity. Moreover, several studies have
shown the involvement of phosphatidylinositol 3-kinases in celi proliferation
(164), differentiation (165), apoptosis (166) and sugar metabolism (167). AKT
cascade is shown in figure D.
Mechanisms of signal transduction can be studied by using tools, such as
pharmacological inhibitors or by specific inhibition with nucleic acids.
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Figure D. A schematic diagram of AKT pathway. Binding of the ligand with
the receptors tyrosine kinase resuits in the dimerization of the receptors and
activation of its kinase dornain in cytoplasrn, which lead to the activation of
PI3K (pi iO-p85) associated with the receptors. The activated PI3K then
phosphoryiates phosphatidylinositoi 3,4-bisphosphate [Ptdlns (3,4)P2] to
phosphatidylinositol 3,4,5-trisphosphate [Ptdlns (3,4,5)P3J. The
phosphatidylinositol 3 kinase bind with the pieckstrin homoiogy domain of
AKT whule PDK1 and PDK2 are aiso recruited and activated. Subsequently,
AKT is phosphorylated by PDKI and PDK2 on the T30$ and S473. The
activated AKT then affect a number of downstream effectors regulating
various processes.
j
AKT
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1.13 Antisense and RNA interference strategies, novel tools in research
Oligodeoxynucleotides and RNA interference are part of the antisense technology,
a new tool, which seems to be promising in overcoming various diseases like viral
infection, cancer, cardiovascular and arthritis disease. The antisense oligos exert a
very strong and specific silencing effect and the only requirement is that the
sequence of the target RNA should be known. Antisense oligodeoxynucleotides
(AS-ODNs) are made synthetically and range from 15-20 bases long. They are
designed to hybridize with the target complementary mRNA sequences to block
the protein synthesis by that mRNA. The secific silencing of gene product in a
relatively short time by this technology has made it very important for the
functional analysis of different genes. Afler entering into the ceils, the
oligonucleotide must remain intact, should not be destroyed by various endo- and
exonucleases and must be hybridized to the target mRNA to trigger a mechanism
leading to inhibition of the synthesis of protein (168).
Afier hybridization with the target mRNA, an endonuclease RNAse H recognizes
DNA-RNA duplex and cleave the RNA strand selectively, liberating the AS-ODN,
which can combine with another mRNA and ultimately lead to the depletion of
that particular mRNA. To increase the stability of AS-ODNs against the nucleases
and RNase H, they are generally modified to phosphorothioate ODN and 2-O-
methyle ODNs. In phosphorothioate ODNs, one of the non-bridging oxygen atom
is replaced by sulfur. The AS-ODNs are synthesized to target sequences, which are
scattered throughout the mRNA (169). To demonstrate the true effect of AS-
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ODNs, control ODNs synthesized against mismatch sequence are used. Few
sequences should be avoided in AS-ODN design, four G residue in a row generate
a secondary structure which prevent the hybridization with mRNA (170) and
sequences like GACGTC, AGCGCT and AACGTT are known to induce interferon
(171). The AS technology has been demonstrated in many ceil types and in animal
models. In the case of arthritis, the transfection of an oligonucleotides for nuclear
factor kappaB (NF-icB) has been reported to reduce the collagen-induced arthritis
in mouse model (172). Another study reported the down-regulation of the
expression of cathepsin B gene in chondrocytes by antisense ONA (173).
Retroviral mediated transfection of an antisense construct for Membrane Type 1
Matrix Metalloproteinase (MT 1 -MÏvIP) in rheumatoid arthritis synovial fibroblast
(RASfs) has significantly reduced the cartilage degradation (174).
The use of double-stranded RNA is another important tool for the functional
analysis of the gene and it lias revolutionized the drug discovery research. RNA
interference (RNAi) is a naturally occuring biological process found in
multicellular organisms such as yeast, plants and humans. It consist of two steps
interacellular processing in which the precursor double stranded RNA molecules
present in the celi are processed by an enzyme Dicer endonuclease, winch cleaves
it in to fragments of 20-24 base pair called double stranded small interfering RNA
(siRNA). The siRNA molecule then becomes the part of RNA-induced silencing
protein complex (RISC), where it unwinds and the complementary sequence to the
target mRNA combines with the mRNA leading to its cleavage. Importantly, when
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the siRNA molecules are exogenously introduced into the mammalian celis, they
become incorporated into the RISC complex. The ability of siRNA to incorporate
into the RISC pathway was recognized as a great advance in biotecbnology and
this technology was named as “ breakthrough of the year” in 2002 by the Science
magazine. The technique is highly specific in identifying its target gene and
suppresses the gene expression by targeting the mRNA. In nature it is also
considered as important for the development of organism and physiological
function (175). Local injection of siRNA for the treatment of macular disease is
underway as a clinical trial (176). Other possible local application tested in mouse
model are intranasal application by inhaling (177) and direct delivery to the central
nervous system by injections (17$) Viral vectors are also in use for systemic
delivery of siRNA (179) however the use of vectors is risky as vector DNA can
incorporate in genome. Other non-specific effects include activation of interferons
indicating that siRNA technique also lias some complications. Due to the
availability of the genetic information about human genome, this technique seems
to be more promising in future for the treatment of diseases. Schiffelers et al
reported the inhibition of TNF-a in collagen-induced arthritis (CIA) afier injecting
siRNA against TNF-ain the joint tissue ofmice (180). In 2006 the Noble prize in
Physiology and Medicine was given to Professor Andrew Z-Fire and Craig C
Mello for their work on siRNA.
Overail, the antisense RNA technology is very promising and is likely to play a
major role in future research and therapies.
j
1.14 Transcriptional regulation of gene ami TIMP-3 promoter structure
Transcriptional regulation is a process in which information in a gene is
transcribed into mRNA in response to signaIs. In eukaryotic celis, only some ofthe
genes are transcribed at any given moment and their proportion and composition
changes considerably during the life cycle, different types of ceils and in response
to changing physiological and environmental conditions (181). A number of
mechanisms are involved in the regulation of gene expression in eukaryotes. The
most common control is the transcriptional initiation (182). For every eukaryotic
gene, transcriptional initiation determines the overail gene expression profile.
Transcription is regulated by proteins known as transcription factors that bind to
specific DNA sequences in the promoter region of a gene resulting in the
activation or inhibition of transcription. A promoter aiways possesses two basic
features. One is a basal promoter, where the RNA polymerase II holoenzyme
complex attaches itself and the other feature is the collection of different binding
sites, which are specific for transcription factors and confer specifity to the
transcription. A basic promoter alone cannot initiate transcription at a significant
level, however the bindings of transcription factors produce stronger response
(183).
The activity of transcription factors is regulated by various environmental factors
(e.g. stress, heat shock and UV light), cytokines and growth factors. In most cases
the transcription factor activity is due to phosphorylation or dephosphorylation
induced by protein kinases and phosphatases. Protein phosphoiylation and
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dephosphorylation alter transcription factors activity in many different ways:
cellular location, protein stability, protein-protein interaction and DNA binding
(184).
Many transcription factors already have nuclear localization, whereas others are in
cytoplasm, and shuttie between cytoplasm and nucleus, and this transiocation is
regulated by phosphorylation. TGF-f3-stimulated phosphorylation of R-Smads
resuit in the dimerization with the co-Smad ($mad-4) and transiocation in the
nucleus (137). In the nucleus, this Smad complex binds with the Smad binding
elements (SBE) CAGA. SBE-like sequences have been identified in the promoters
of many TGF-[3 responsive genes, including plasminogen activator inhibitor-l
(PAT-1), junB, type VII collagen and the germiine immunoglobulin lix region.
Mutation of the $BEs in the PAl-1 promoter has been showu to decrease
significantly TGF-3 inducibility (185).
The binding affinity of Smads for DNA is relatively low (186) and requires other
sequence-specific binding partriers for efficient binding to the promoters of
responsive genes. In ligand-responsive promoter regions, SBE sites are generally
located in close proximity to recognition sequences for other transcription factors,
for example FAST-1 in the Mix2 promoter (187); AP-1, TfE3 and ATF2 in the
PAl- 1 promoter (188,189). The binding of these transcription factors enhanced the
TGf-f3-induced response where as the mutation in these sites for the transcription
factors attenuates TGF-f3-induced response. The interaction between Smad and a
transcription factor can be direct, as in the case for Smad3 and AP-1 family
members (190) or indirect as the Stat3 and Smadl brought together through their
association with the CBP/p300 co-activator upon stimulation by BMP and
leukemia inhibitory factor (191).
In certain responses, Smad do not bind to the DNA directly, but by an indirect
way as in the case of TGF--mediated upregulation of CDX inhibitor p21, where
the DNA binding of Smads via interaction with Spi bound to the promoter (192).
furthermore there are some proteins that act as Smad co-activators and co
repressors. CBP/p300 act as co-activators (193) where as Ski, SnoN and TGW act
as co-repressors (194).
The transcription of every gene is regulated by transcription factors and cofactors
that interact with its promoter. The region of 1.2 Kb immediately upstream with
respect to transcription start site in human TIIVIP-3 coding gene shows TIMP-3
promoter activity, as we have detennined in our lab also. This region contains
multiple sequences, which are binding sites for known transcription factors
(195,196). Among these are four Spi, one C/EBP, one NFi, one c-Myb and
several AP-2 sites in the region between +1 to —600. Tins region also contains
several potential Smad binding elements (SBE) or CAGA sequences which are
involved in the induction of plasminogen activator inhibitor-1 (PAl-1) gene
promoter in response to TGf-3 (140). In this study, we have demonstrated the
involvement of Smads and Spi transcription factor in TGF-13-induced TEVIP-3
gene in chondrocytes. The TIIVIP-3 promoter structural detail is shown in figure E.
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-830 CCTCTCTCCT GTGGC’flGCC CCAGAGCTGA TCCYI’GTCYr TGTCCACTTC
SBE
-780 TCAGCGAGGA TGGCACfCA GGGAGCCCTT CCCTTACTAT CGCAGAGAGA
S3E
-730 GCAGGCCCTC CCCAGTCATG TCCAACCCAG AACTCTGTfl TGflTtCTTC
SBE
-680 ATAGCCCTAG CATCACAGAA AATCACCCTG TGCAHCATG GATGTCCACG
SBE
-630 GGGGCAAGGG CTTGTGTG CAACCCAG CATCCTGAAC CGTGGY
-580 GAATGAATAC AGAACCCCGT ‘frGCTCTGGG AGAGCACAGA AAACAGTCTT
SBE
-530 CTATCATATA TCATAGCCAG CTGCAAACAG CAGATGGCTT CCCATATCCC
SBE
-480 AGAGAGTAAG AACCAGAGAG AGAGAGAAAG AGAGAGAG TGGGTCC
SBE
-430 TCCTCTGTGC CTGCfCTCTC CAGAGAAACT GGAGGGGTAG CAGTfAGCAT
SBE
-380 TCCCCCGCTG GTCCACCAA GCACAGTCAA GGTCTCTAGG ACATGGCCAC
-330 CCCTCACCTG TGGAAGCGGT CCTGCTGGGG TGGGTGGGTG fAGTGGT
-280 CTGGGGG CAGAGACACC CAGTGGCCCA GGTGGCGTG_GGGCCAGGGC
SBE NF-1
-230 GCAGACGAGA AGGGGCACGA GGGCTCCGCT CCGAGGACC AG3GCAAGC
SBE AP-2
-180 ACCGGTCCCG GDGCGCCC AGCCCACCCA CTCGCGTGC CACGCGGCA
AP-2
__________
AP-2
AP-2
-130 HATFCCCTA TAAGGATHG AACGATCCGG GGGCGGCCCC__GCCCCGTFAC
Sp-1 Sp-1
C-Myb
-80 CCC’flGCCCC CGGCCCCGCC CCCTTGG AGGGCCGATG AGGTAATGCG
•
Sp-1
AP-2 C/EBP
-30 GCTCTGCCAT TGGTCTGAGG GGGCGGGCC CAACAGCCCG AGGCGGGGTC
Sp-1
+22 CCCGGGGGCC CAGCGATATA TCACTCGGCC GCCCAGGCAG CGGCGCAGAG
Figure E. Transcription factor binding motifs in the human TIMP-3 promoter.
Nucleotide sequence ofhuman TIMP-3 promoter in the region proximal to the
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transcription start site (-830 to +1) and 71 nucleotide ofthe 5 transcribed region.
Numbering indicates the nucleotide distance relative to the transcription start point
with +1. Different motifs are underlined. CIEBP, CAATT/enhancer-binding
protein; SBE, Smad binding element. transcription start site. (Ref 195, 196)
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1.15 Research hypothesîs and experimental approach
Tissue inhibitor of metalloproteinases-3 (TIMP-3) inhibits matrix
metalloproteinases and aggrecanases implicated in arthritic cartilage loss. The
regulation of TEvIP-3 gene by transforming growth factor beta (TGF-13) family
members in cartilage is poorly understood. This work focuses on examining
signaling pathways involved in TGF-3 induced TIMP-3 induction in chondrocytes.
Based on earlier work, we hypothesize that Smad signaling, ERK and possibly
AKT pathways mediate TEvIP-3 induction 1y TGF-f3. These signaling cascades
could activate certain transcription factors that could bind and induce TIIvIP-3
promoter. We analyzed these hypotheses in the vitro model systems consisting of
cultures of human chondrosarcoma SW1353 ceils and primary or early-passage
cultures of bovine and human chondrocytes.
Specific aims of tins study were 1) To examine the stimulation of different
signaling pathways (ERK, AKT and Smad) by TGF-13 using Western blotting to
determine the activation of signaling mediators using phospho-specific antibodies.
Specific pharmacological inhibitors as weÏl as genetic inhibitors, such as sense and
antisense phosphorothioate oligonucleotides were used to examine the
involvement of various mediators of these pathways by Western and Northem blot
analysis. The EMSA was used to examine the impact of mithramycin on Spi
binding activity in SW1353 celis. Co-transfection of cytomegalovirus (CMV)
promoter-Sp 1 expression vector along with TIMP-3 promoter-luciferase plasmid
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was performed to explore the effect of Spi on TIMP-3 promoter luciferase
expression (article i).
2) b study the involvement of AKT paffiway, specific inhibitors of this pathway
were used, and TIMP-3 protein and RNA was measured by Western and Northern
blot analysis. Specific siRNAs were transfected to knock-down (PI3K and AKT)
genes and respective proteins of down-regulated genes and TIIvIP-3 were analyzed
by Western blot. Effects of TGF-3 and inhibitors were also studied on TIIvIP-3
promoter activity by luciferase assays (article 2).
3) To characterize distinct Smads activated by TGF-3 by Western bloffing. To
identify specific Smads involved in the induction of TIMP-3 gene by using
specific inhibitors and gene knockdown by siRNA. Additionally, deletion mutants
were made of TIMP-3-luciferase promoter-reporter plasmid to identify the
responsive region for TGF-[3. Their activities were analyzed aCter transient
transfection and luciferase assays (article 3).
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II. Articles
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1. Article I
Qureshi HY, Sylvester J, Bi Mabrouk M, Zafarullah M. TGF-j-induced
expression of tissue inhibitor of metalloproteinases in chondrocytes is
mediated by extracellular signal-regulated kinase pathway and Spi
transcription factor. J Ceil Physiol. 203(2): 345-52, 2005.
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TGF-f3-Induced Expression of Tissue Inhibitor of
Metafloproteinases-3 Gene in Chondrocytes Is Mediated
by Extracellular Signal-Regulated Kinase Pathway
and Spi Transcription Factor
HAMID YAQOOB QURESHI, JUDITH SYLVESTER, MOHAMM[D [L MABROUK,
AND MUHAMMAD ZAFARULLAH*
Deparlmeni ofMedicine and Centre de Recherche du Centre Hospitalier
de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada
Transforming growth factor (TGE-(3l) is a potent inducer of choncirogenesis anci stimulant of cartilage extracellular matrix (ECM)
synthesis. Tissue inhibitor of metaiioproteinases-3 tT1MP-3) is iocateci in ECM anci isthe major inhibitorof matrix metalioproteinases
(MMPs) anci aggrecanase, the principal enzymes impiicated in collagen anci aggrecan degradation in arthritis. We investigated the
roie ré extraceliuiar-signai-regulated kinase tERK)-mitogen-activated protein kinases (MAPK) anci Spi transcription factor in TGF-F3-
induceclTlMP-3 gene in chondrocytes and chondrosarcoma ceiis. IGE-ji time-dependentiy induced a sustained phosphoryiation of
ERK-MAPKs in primary human or bovine chondrocytes. inhibitors of this pathway, PD98059 and U0l 26, downregulated TGF-fl
induceci expression ofTiMP-3 RNA and protein. Since the ERKs can phosphoryiate Spi, and the promoter of human TIMP-3 gene
contains four Spi-binding sites, we investigated whether Spi isa clownstream target of this pathway. Mithramycin and WP631, the
agents that prevent bincling of Spi to its consensus site, downreguiated TGF--inducibie TIMP-3 expression. indeeri, mithramycin
biocked TGF--stimuiated Spi binding activity. Transfection of cytomegaiovirus (CMV) promoter-Spi piasmid increasecl T1MP-3
promoter (—940 to +376)-driven iuciferase activity. Depietion of Spi hy transfection of an antisense phosphorothioate oligo
ncicieotide suppressed TGF-13-incluced T1MP-3 protein expression, while its sense homoiog hacl no effect. These results suggest that
activation of ERK-MAP1< pathway anci Spi transcription factor piay a pivotai roie in the induction of T1MP-i by TGE-[3 in
chondrocytes. j. Ccii. Physiol. 203: 345—352, 2005. © 2004 Wiley-Liss, Inc.
Resorption of cartilage extracellular matrix (ECM) in
patients with rheumatoid arthritis (RA) and osteoar
thritis (OA) occurs by failure of endogenous repair
processes induced by an imbalance between anabolic
growth factors and catabolic proinflamrnatory cyto
kines, interleukin-1 (IL-1) and tumor necrosis factor
(TNF-), which inhihit the ECM synthesis and in
duce matrix metalloproteinases (MMPs) production
(Goldring, 2000; Firestein, 2003). Aduit human cartil
age bas limited capacity to regenerate, and growth
factors, such as transforming growth factor beta tTGF
J)) family members, are of particular interest in this
regard. TGF-j3, a multifunctional growth factor, is
produced by monocytes-macrophages, platelets, and
chondrocytes, and is a potent inclucer ofchondrogenesis
during development and cartilage ECM synthesis
(Joyce et al., 19901. As an attempt to repair tissue
damage, TGF-J31 is elevated in hurnan RA synovial fluid
(Lotz et al., 1990), and is a major growth factor foi’
stimulating cartilage regeneration (Lotz et aI., 1995). It
suppresses acute and chronic arthritis by counteracting
the effects of IL-1 (Brandes et al., 1991). Excessive TGF
3 is also irnplicated in the formation of bony joint
outgrowths called osteophytes in OA (van Beuningen
et al., 1994), synovial hyperplasia, and inflammation in
RA (Harnilton et al., 1991) by inducing or suppressing a
battery of genes. Inhibition of endogenous TGF-f3 in a
murine arthritis model resulted in prevention of osteo
phyte formation and impaired cartilage repair, suggest
ing its role in these patholog3cal and physiological
processes ($charstuhl et al., 2002a).
MMP and aggrecanase (ADAMTS) families of pro
teases have the capacity to digest ail components of
cartilage ECIVI (Caterson et al., 2000; Mengshol et al.,
2002; Nagase and Kashiwagi, 2003). Tissue inhibitors of
metalloproteinases (TIMPs) are natural inhibitors of
MMPs and consist of four members tBrew et al., 2000;
Baker et al., 2002; IVlohammed et al., 2003). Activated
MMPs in excess of TIMPs are implicated in damage to
articular cartilage. rFGF..ç3 inhibits the expression of
MIVIPs but induces TIMP-1 and TIMP-3 in articular
chondrocytes (Gunther et al., 1994; Su et al., 1996).
TIMP-3 is uniquely located in ECM where it binds to
sulfated glycosaminoglycans such as chondroitin and
heparan sulfate (Yu et al., 2000) and is the major
inhibitor of MMP-13 and ADAM-TS4, the principal
enzymes implicated in cartilage collagen and aggrecan
degr’adation in arthritis (Hashimoto et al., 2001;
Kashiwagi et al., 2001). It also inhibits TNF-t convert
ing enzyme (TACE or ADAM-17), which activates
proarthritic cytokine, TNF-o (Amour et al., 1998; Lee
et ai., 2001). TIMP-3 can thus reguiate inflammation in
RA. TIMP-3 inhibits angiogenesis ta prominent feature
of RA and tumors) by blocking the binding ofVEGF toits
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receptor (Anand-Apte et al., 1997; Qi et al., 2003). These
distinct features make TIMP-3 a potentially important
therapeuticprotein in arthritis (Lee et al., 2002; Nagase
and Brew, 2002; Mohamrned et al., 2003). Indeed, TIMP
3 overexpression prevents invasion of cartilage by
human rheumatoid synovial fibroblasts in a mouse
model (van der Laan et al., 2003). The mechanisms by
which TGF-13 augments TIMP-3 expression are poorly
understood. In other systems, TGF-[3 first binds
with type II receptors and then phosphorylates and
activates type I receptor on serine and threonine, lead
ing to transcription of the target genes via inhibitory
or stimulatrny Smads and other pathways (Shi and
Massague, 2003). We previously showed the invoive
ment of serine/threonine kinases in TGF-13 induction
of TIMP-3 in chondrocytes (Su et al., 1998), however,
precise signaling pathways and target transcription
factors irnplicated in this induction are unknown. In the
present study, we utilized chondrocyte model systems,
namely bovine and human primary articular chondro
cyte and chondrosarcoma celis, and showed the crucial
role of extracellular-signal-regulated kinase (ERK1!2)-
mitogen-activated protein kinases (MAPK) and their
target, Spi transcription factor in TGF-f3-stimulated
increase of TIMP-3.
MATERIALS AN]) METHODS
Culture of chondrocytic celis aird treatments
Normal bovine articular cartilage vas obtained from the
knee and hip joints of normal aduit, 30-month-old animais
from a local abattoir. Human cartilage vas acquired from the
femoral heads of OA patients who underwent hip-repiacement
surgery at the Notre-Darne Hospital. Chondrocytes were
released by 90 min pronase and collagenase (type II) (Sigma
Chemical Company, St. Louis, MO) digestion 5w 9 h in
Dulbecco’s modifled Eagies medium (DMEM) (Invitrogen Life
Sciences, Inc., Burlington, ON). The colis were washed with
phosphate buffered saline (PBS) and grown in DMEM with
10% fetal caif serum (FC$) as high-density primary mono-
layer cultures until confluent growth. Colis were distributed
in 6-well plates (Becton Dickinson, Franklin Lakes, NJ), grown
to confluence, washed with PBS, and kept in serum-free DMEM
tèr 24 h. ERK1/2-specific inhibitors, PD98059 (2’-amino-3’-
methoxyflavone) (Dudleyet ai., 1995) and U0126 (1,4-Diamino-
2, 3-dicyano- 1 ,4-bist2-arninophenylthio]butadiene) (Favata
et al., 19981 from Calbiochem (La Joua, CA) were dissolved in
dimethyl sulfoxide (DM80) and added at the concentration of
15—30 and 2.5—5 pM, respectively, 30 min before treatment
with human platelet TGF-f3 (10 ng/mi) (R&D systems,
Minneapolis, MN) for 24 h. In other experiments, celis were
pretreated with 100—150 nM mithramycin or 25—50 nM of
bisanthracycline WP631 (Martin et ai., 1999). TGF-31 vas
reconstituted in 0.1% fraction V of bovine serum albumin (BSA)
(Sigma) and 4 mM HC1 as recommended. A TGF-l3-responsive
human chondrosarcorna celi une, SW1353, was obtained from
Arnerican Type Culture Collection (ATCC, Manassas, VA) and
treated as descrihed for primaI-y chondrocytes.
RNA extraction and Northern
hybridization analysis
Total RNA was extracted by o rapid procedure
(Chomczynski and Sacchi, 1987) and aliquots of 3—5 ig
analyzed by electrophoretic fractionation in 1.2% formaide
hyde-agarose gels. The integrity and quantity of applied RNA
were verifled by ethidium bromide staining of the gels and
photography of the 28$ and 18$ ribosomal RNA bands. The
RNA was electroblotted cornpletely ente Zetaprobe nylon
membrane (Bio-Rad, Mississauga, ON) using o Bio-Rad Trans
blot in the presence of lx TAE buffer at a current of 40 mA
overnight. Northern blets were hybridized with a bovine
(Su et al., 1996) or human TIMP-3 (Apte et ai., 1994) cDNA
probe (latter generously provided by Dr. Suneel Apte, Cleve
land, 0H). The bovine TIMP-3 probe ;vas a 2.0 Kbp EeoRI
cDNA fragment cloned in the piasmid pGEM-4Z (Promega
Biotech., Madison, WD. The vector was linearized with Non,
and an RNA probe was synthesized using T7 polymerase. The
human 28$ ribosomai RNA piasmid (from ATCC, Manassas,
VA) was digested with XbaI and a probe synthesized using T7
polymerase. Ail probes were labeleci te high-specific activity
(i< l0 cpm/ig) with [u-2PÏ CTP (3,000 Ci/mmol, Perkin
Rimer Canada, Inc., Woodbridge, ON) with the RNA laheling
kit from Promega Biotech., according to their protocois.
Western Mot analysis
The activation of ERK-MAP kinases was analyzed by
Western immunoblotting using antibodies against phosphory
lated or total proteins (Ccli Signaling Technology, Beverley,
MA). For TIMP-3 protein leveis, total cellular protein extracts
tram bovine or humnn chondrocytes (10—20 pg) were subjected
to fractionation by a 15% SD$—PAGE mini gel (Bio-Rad
system), transferred to PVDF (Poli Corporation, Anne Arbor,
MI) by electrobiotting, and reacted with the 1:400 dilution of
human TIMP-3 polyclonai antibody (Chemicon International,
Temecula, CA) as described before (Li and Zafaruilah, 1998).
Subsequentiy, membranes were incubated with the anti
rabbit secondary horseradish peroxidase-conjugated antibody
(Promega, Madison WI) and the TIMP-3 protein hands re
veaied with the chemiluminescence detection system of Roche
Biochemicals (Lavai, Qc, Canada) with their protocols. Central
proteins that served as loading contrai were unaffected
proteins from the same celiular extracts obtained by the
Coomassie biue staining cf the gels. For measuring Spi levels,
pratein extracts were fractionated by 10% SDS—PAGE, re
acted with 1:500 dilution cf human Spi polyclonai (rabbit)
antibody (Geneka Biotechnoiogy, Inc., Carisbad, CA), and
reacted with secandary antibody as above, which yielded e
97-kDa hand.
Fig. 1. Induction et extracellular-signal rcgulated kinase (fRK(
mitogen-activated protein kinases (MAPK) phasphorylation by ‘f GF-()
in articular chondrocytes. Colis were treated with 10 ng/mi of TGF-[i
for the indicated timo periods. Celiular extracts (10 pg) were subjected
ta immunoblotting with phosphorylation-state-specific ERK1 and -2
aatibodies, the respective 44 mcl 42 kDa bands detectod by chemilu
minesceacc and identifiecl by Choir sizes. The biots were stripped and
reprobed with reguiar antibodies, which detected Cottil amount et the
respective proteins.
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Electrophoretic mobilfty sfflft assay (EMSA)
SW1353 celle in 6-well plates were grown to S0% confluence,
washed with PBS, and kept in serum-free DMEM for 24 h.
Mithrarnycin was added at a concentration of 100—150 nM, Tes
pectively 30 min before treatment with human platelet TGF-f31
(10 ng/ml). Nuclear extracts were prepared as describeti
(Andrews and Faller, 1991) with saine modifications. After
24 h, the celis wel’e washed twice with colti PBS fpH 7.4) and
detacheti by scraping, recovered by centrifugation at 10,000 i’pm
for 5 min at 4C. The celis were lysed in ice-cold buffer A [10 mM
HEPES (pH 7.9), 1.5 mMMgC12, 10 mM KCI, 0.5 mM DTP, 1 mM
PMSF, 1% NP 40, 1 mM NaF, and 10 fig/ml protease inhibitors
leupeptin A anti pepstatin] anti mixed by pipetting. After
incubation on ice for 10 mini, the contents were centrifuged at
4,000 rpm for 2 min. The nuclear pellets were suspended in 60 fil
ofice-colti buffer B [20 mM HEPES (pH 7.9), 420 mM NaCI, 25%
glycerol, 1.5 mM MgC12, 0.2 mM EDTA, 1 mM NaF, 0.5 mM
DTI, 0.5 mM PMSF, and 10 (lg/ml protease inhibitors, leu
peptin, and pepstatin A] anti kept on ice for 30 min with gentie
shaking anti then centrilhged at 12,000 rpm for 15 min at 4C.
The nuclear protein supernatants were recovered and protein
concentrations were determined by Bio-Rad protein assay.
The double-stranded oligonucleotide containing the Spi
consensus (Promega Corporation, Madison, MIT) sequence was
end labeled with [y-p] ATP by T4 polynucleotide kinase.
Nuclear extracts (5 pg) were incubated with 20,000 cpm of
labeled probe for 20 min at room temperature in binding buffer
[10 mM Tris-I-ICI (pH 7.5), 4% glycerol, 1 mM MgCI2, 0.5 mM
EDTA, 0.5 mM DTT, 50 mM NaC1, and 50 flg/ml poly (dl. tiC)]
and DNA protein complexes were resolved on a 5% non
denaturing polyacrylamide gel at room temperature. Competi
tion assay vas performed by incubating 200-fold molar excess
of colti probe for 15 min at room temperature before the
addition of the pd21abe1ed oligonucleotide.
Transient transfections
Ceils were transfectecl with Spi sense 5’-CCA TGG ATG
AAA TGA CAG CTG TGG TG-3’ anti antisense 5’-CAC CAC
AGC TGT CAT ‘YÎC ATC CAT GG-3’ phosphorothioate (at ail
nucleotides) oligonucleotides (ODN via calcium phosphate
precipitation method (Graham and van der Eb, 1973) for
adherent celle in suspension as follows. Celle were detached by
trypsinization, trypsin removed by centrifugation and suspen
sien incubateti with ODN-calcium phosphate precipitate for
SW1353- Western blot
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Fig. 2. Impact of ERK!MAPK pathway inhibitors on TGF-p
stimulated expression of TIMP-3 in SW1353 celis. Chondrosarcoma
SW1353 celle were pretreatcd with the indicateci doses of(A) PD98059
or (B) U0126 for 30 min anti stimulated with TGF-[3 tbr 24h. TIMP-3
RNA (5 ig) aad protein (10 tg) from cellular extracts vere analyzed by
Nort hein hybridizatioa with TIMP-3 and 28S ribosomal RNA probes
and Western blotting with TIMP-3 antibody. Arrows mdicate three
diffèrent transcripts of TIMP-3. The 285 rRNA serving as loading
central is shown at the bottem. TGF-fI-inducible TIMP-3 protein band
(24 kDa) and a constitutively expressed coatrol or Coomassie blue
steined protcin band from thc came extracts are shown.
1. -> Total ERK 112
Fig. 3. Inhibition of ERK-l/2 phosphoiylation by PD98059 and
U0126 SW1353 celle were pretreated with (ho indicated doses of
PD98059 (A) or U0126 (B) for 30 mm, stimulated with ‘I’GF-(( for 1 h
anti protein extracts subjected te Western humunoblotting with phos
phoiylation-state-specific ERK1!2 anti total ERK antihodies. Arrowe
indicate Oie respective bande.
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10 min and plated in serum containing medium for 3 h.
Medium was removed, celis washed with P38, allowed them to
recover for 16 h, maintained in serum-free medium for 36 h and
then stimutated with TGF-( fbr 24 h. Equal amount (20 )tg) of
protein was analyzed for TIMP-3 protein levels as above.
In other experiments, 2 ig of TIMP-3 promoter luciferase
)—940 to +376 region; Zeng et al., 1998), cytomegalovirus
tCMV)-Renilla luciferase (0.2 pg, transfection control), CMV
Spi expression vector (0—1.2 tg) (from Du. Stephen Smale,
UCLA), and different amounts of mock DNA tpGL3 basic,
Promega) were cotransfected by the rnodihed calcium phos
phate procedure describeci above and luciferase activity anal
yzed with Promega Dual-Luciferase Reporter assay System
and Turner Designs Luminometer TD-20/20 according to their
recommended procedures.
Ail the experiments were pei’formed at least three times and
the resuits were reproclu cible.
RESUETS
TGF- induces activation of ERK-MAPK
pathway in chondrocytes
To investigate the mechanisms ofTGF-F3 signaling in
chondrocytes and to examine whether TGF- activates
Primaiy bovine chandrocytes
ERK-MAPK pathway, quiescent human or bovine arti
cular chondrocytes were treated with TGF43 for the time
periods of 1—24 h. As shown in Figure 1, TGF-f3 induced
phosphorylation of ERK-1 and -2 within 1 h in both
human (Fig. lA) and bovine (Fig. lB) chondrocytes that
remained elevated up to 24 h (human) or 4—9 h (bovine).
The total levels ofthese proteins remained constant.
ERK-MAPK pathway inhibitors downregulate
TGf-fl-stimulated expression of TIMP-3
To explore the requirement ofERK pathway stimula
tion for TGF-f3-induced TIMP-3 gene expression, human
chondrocytic SW1353 ceils were pretreated with the
specific inhibitors of this pathway, PD98059 (Dudley
et al., 1995) or U0126 (Favata et aI,, 1998) and then
stirnulated with TGF-3. As shown in the Northern and
Western blots of Figure 2A,3 , TGF-[) induced TIMP-3
RNA and protein whose levels were downregulated by
the both inhibitors. The TIMP-3 protein levels rnimicked
the pattern of RNA expression. The levets oftheloading
control, 28S rRNA and constitutively expressed Coo
massie blue-stained control proteins from the same
3 and 28S ribosomal RNA probes and Western blotting with T1MP-3
antibody. Arrows indicate three clifferent transcripts ofTIMP-3. The
288 rRNA serving as loading contrai is shown al the bottom. ‘1’GF-)-
inducibic TIMP-3 protein banc! (24 kDa) and s constitutiveiy cx
pressed control prolein band from the same extracts are shown.
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extracts remained consistent. To ascertain if inhibitors
indeed affect ERK phosphorylation, SW1353 celis were
pretreated with TIMP-3 inhibitory doses ofPD98059 or
U0126 and then stimulated with TGF-13. These agents
completely blocked TGF--stimulated phosphorylation
of ERK1!2 (Fig. 3A,B). Both inhibitors (and not their
vehicle, DMSO) also downregulated TGF-13-induced
TIMP-3 RNA (Fig. 4A,C) and protein (Fig. 4B,D)
expression in primary bovine chondrocytes without
affecting the constitutively expressed 2$S rRNA and
control proteins.
Spi transcription factor inhibitors, mithramyin
and WP631, inhibit TGF--stimuIatecI
TIMP-3 RNA and protein expression
Since p42/p44 (Erki/2) MAPKs can phosphorylate
Spi in vitro and in vivo (Merchant et al., 1999; Milanmi
Mongiat et al., 2002) and the promoter region ofhuman
TIMP-3 gene contains four Spi transcription factor
binding sites (Wick et al., 1995), we investigated the role
of Spi as a possible dowustream target of the ERK
pathway. Different unes of chondrocytes were pre
A
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Fig. 5. Inhibition of TGf--induced TIMP-3 gene expression by
mithramycin in chondrocytes. Primary human chondrocytes (A),
SW1353 (B), and bovine tC) chondrocytes were pretrcated for 30 min
with mithramycin (which at 100—150 nM doses prevents the bincling
of Spi to its consensus DNA site) and stimulated with TGF-3. RNA
and protein were analyzed as in Figure 2.
treated for 30 min with a pharmacological inhibitor of
Spi transcription factor, mithramycin, which at 100—
150 nM doses prevents the binding of Spi to its con
sensus DNA site (Datta et al., 2000) and then stimulated
with TGF-f3. Mithramycin dose-dependently inhibited
TGF--inducib1e TIMP-3 gene expression in primary
human chondrocytes (Fig. SA), SW1353 chondrosar
coma ceils (Fig. 5B), and bovine articular chondrocytes
(Fig. 5C) without affecting constitutively expressed 285
rRNA and control proteins. Similarly, an other inhibitor
of Spl-activated transcription, bisanthracycline WP631
(Martin et al., 1999), suppressed TIMP-3 RNA and
protein induction in human chondrocytes (Fig. 6).
To study the effect ofmithramycin on TGF-f3-induced
Spi binding to its consensus sequence, SW1353 celi
nuclear extracts were analyzed by EMSA. As shown in
Figure 7, Spi activity was increased by TGF-jl treat
ment and completely suppressed by mithramycin. Pre
incubation with molar excess ofcold Spi oligonucleotide
drastically reduced Spi binding. Thus this agent does
inhibit Spi activity.
Transient expression of exogenous Spi increases
hmnan TIMP-3 promoter activity
To further investigate the role of Spi transcription
factor in TIMP-3 regulation, human SW1353 cells were
transiently cotransfected with the constant amounts
ofhuman TIMP-3 promoter-firefly luciferase vector (5’-
flanking region from —940 to ±376, Zeng et al., 1998),
pRL-C1VW, an internal control plasmid expressing
Renilla luciferase, different arnounts of CMV-Spi
texpressing Spi under the Cl\’W promoter) and mock
(pGL3 basic) DNA to keep equal amount of DNA. As
shown in Figure 8, increasing arnounts of Spi signifi
cantly enhanced TIMP-3 prornoter-driven luciferase
activity compared to basal levels.
Pnmary human chondrocytes
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Fig. 6. Suppression of TGF-.induced TIMP-3 gene expression by
WP631 in httman chondrocytes. Primary colis vere pretreated for
30 min with WP631 (25—50 nM) and stimuiated with TGF-f(. RNA and
protein were analyzed as in Figure 2.
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Fig. 7. Impact of mithramycin on Spi binding activity in SW1353
ceils. Chondrosarcoma celis maintained in serum-free medium were
pretreated with mithramycin, stimulated with TGF-3, and nuclear
extracts suFjected to EMSA. From left to right: Lane 1, labeled
5pi probe only without extraci; lane 2, probe with TGf-[t-stimulated
5p1 -positive extract; lane 3 (competitor), extract preincuhated with
200-told molar exccss cf cold Spi consensus oligonucleotide and then
incuhated with labeled probe; lane 4 (non-competitor), extract incu
bated with non-competitive unlaheled AP2 oligo and labeled Spi
probe. Other lanes contained labeled Spi oligo with nuclear extracts
fi-om colis subjccted b different t-reatrnents,
Antisense Spi oligonucleotide blocks
TGF-[1-enhanced induction of TIMP-3
expression in human chondrocytic ceils
DISCUSSION
Due to their ability to inhibit cartilage digesting
MMPs, both TGF-[3 and its target, TIMP-3, are poten
tially important therapeutic proteins for cartilage
maintenance, prevention of cartilage degradation. and
its repair in arthritis. By means of several pharmacolo
gie and genetic approaches, we have shown for the first
CMVSPI 0 4 22 g
MacRDNA 1.2 8 A O ig
Fig. 8. Influence of Spi expression on hamac TIMP-3 promoter
activity. Human SW1353 ceils werc transientlv cotransfocted with the
indicated constant amounts of human TIMP-3 promoter-firefly luci
ferase vector from - 940 te +37G), a plasmid exprossing Renifla
luciferase (internai control) and different amounts of vector expres
sing Spi under CMV promoter. To kecp the amount cf DNA constant,
rnock DNA (pGL3 basic. Promega) tees used. The values of firefly
luciferase te Reniila luciferase ratios plotted with Prism 3.0 software.
Data are presented as the mean ± SEM of three independent experi
monts. P < t).05 tvas considered signiticaut.
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Fig. 9. E fiect of antisense Spi oligonucleotide transfection en TGF-It
induced Spi and TIMP-3 gene expression in chondrocytes. Primary
human chondrocytes (A) or SW1353 celis (B) were transiently trans
fected with e sensu and antisense phosphorothieate oligonucleotide
and stimuiated with TGF-Çl for 24 b. Protein extracts (20 pg) were
analyzed by Western blotting for Spi and TIIVIP-3 protein expression
and resuits are presented. Spi Western biotyields a 97-kDa band. The
conirol unaffected preteins from the same extract arc aise shotvn.
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To further evaluate the requirement ofSpl transcrip
tion factor for induction ofTIMP-3 induction by TGF-3,
primary human chondrocytes or SW1353 cells were
transiently transfected with a sense and antisense
phosphorothioate oligonucleotide (the latter previously
shown to effectively inhibit Spi gene expression, Pang
et al., 2003) and TIMP-3 protein levels analyzed by
Western blotting. As shown in Figure 9A,B, Spi and
TIMP-3 protein induction by TGF-Ç3 was unaffected by
the sense oligonucleotide but was significantly inhibited
by the antisense oligonucleotide. Similarly, the levels of
a constitutively expressecl protein (flot induced by TGF
fi and that served as loadirig control) were not allcted by
the ODN.
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time that besicles well-known Smad pathway, ERK
MAPK cascade and Spi transcription factor are needed
for induction ofthe TIMP-3 gene expression by TGF- [3 in
articular chondrocytes.
Increased phosphorylation of ERKs in response to
TGF-13 treatrnent in bovine and human chondrocytes
suggests conservation of this TGF-f3 signal transduc
tion mechanism in two different species. TGF-f3 also
activates this pathway in rat articular chondrocytes
(Yonekura et al., 1999), during chondrogenesis of
human mesenchymal progenitor (Tuli et al., 2003) and
prior to aggrecan induction in chondrogenic, ATDC5
celis (Watanabe et al., 2001). Since ERK-MAPK path
way is associated with maintenance and increased
survival of chondrocytes (Shakibaei et al., 2001), sus
tained activation of this pathway over several hours
could have profound impact on these processes and TGF
13 target genes such as TIMP-3. Since increased
apoptosis is one of the mechanisms of cartilage loss in
OA (Hashirnoto et al., 1998), stimulation of the pro
survival ERK pathway by TGF-[3 may have an anti
apoptotic effect in chondrocytes. Downregulation of
TGF-[3-induced TIMP-3 RNA and protein by pharmaco
logical inhibitors, PD98059 and U0126, suggest that
ERK-MAPK is partly involved in TGF-[3-induced TIMP
3 expression in human chondrocytes, a process that is
also conserved in bovine chondrocytes. Similar pattern
of TIMP-3 RNA and protein induction and inhibition
points to a transcriptional rather than a post-transla
tional mechanisrn of regulation.
Spi was previously considered to be a factor respon
sible for basal expression ofa number ofgenes. However,
several recent studies implicate this factor in inducible
expression and fine-tuning of gene regulation. For
instance, its phosphorylation at C-terminus is increased
during the progression of celi cycle and growth where
ERK-MAPK pathway is also ttirned-on (Black et al.,
2001). TGF-[3 stimulates increased serine phosphoryla
tion of Spi in fibroblasts from Scleroderma patients (Ihn
and Tamaki, 2000). Phosphorylation ofSpi at threonine
453 and 739 enhances binding of Spi with its target
sequence (Milanini-Mongiat et al., 2002). Human TIMP
3 promoter region between —112 to + 1 5’-flankingregion
has at least 4 Spi consensus sites (Wick et aI., 1995).
Potent inhibition of endogenous TIMP-3 RNA and pro
tein induction by the pharmacological agents, mithra
mycin and WP63 1, suggest that this transcription factor
is required for TGF-[3-induced TIMP-3 expression in
chondrocytes. These results were reinforced by the al
ternative genetic approach of Spi transcription factor
antisense ODN-driven inhibition of Spi and TIMP-3
and by Spl-enhanced TIMP-3 promoter activity. Our
results are in contrast with a gene array analysis of
antisense Spi vector-transfected NIH3T3 mouse fibro
hasts, where basal expression of several ECM-related
genes was inhibited but no effect on TIMP-3 was
observed (Verrecchia et al., 2001). This may be due to
differences in mouse and human TIMP-3 prornoters and
fibroblast-versus chondrocyte-specific mechanisrns of
TIMP-3 regulation. Our results with TIMP-3 gene sup
port the recent concept that Spi is an important link
between increased activation of ERK pathway and its
target genes (Milanini-Mongiat et al., 2002). Alterna
tively, Spi sites may also be involved in the interaction
with Smads. Indeed, TGF-[3 was shown to stimulate Spi
Smad3 interaction prior to induction of plasminogen
activator inhibitor and 2(I) collagen genes, which were
inhibited by mithramycin (Datta et al., 2000; Poncelet
and Schnaper, 2001).
TGF-[3 is an important growth factor that promotes
fCM synthesis. It counteracts the catabolic effects of
IL-1 such as inhibition of ECM synthesis and increas
ed production of MMPs and aggrecanases in arthritic
cartilage by inducing TIMP-1 and TIMP-3. The process
of antagonization by TGF-J3 was recently shom to be
impaired in older mice (Scharstuhl et ai., 2002b). It is
possible that TGF-[3 signal transduction and expression
of its target genes, such as TIMP-3, are disturbed in
older animais and humans, making them more Suscep
tible to OA. Indeed, skeletal tissues of transgenic mice
with defective type II receptor kinase have human OA
like degenerative changes due to defect in signaling
(Serra et al., 1997). Excessive amounts of active
stimulate osteophyte formation in OAjoints, which is a
bony adaptive outgrowth produced as a result of OA
(Bakker et al., 2001). Inhibition of endogenous TGF-[3
via a scavenging TGF-[3-RII receptor increased cartilage
damage by MMPs and resulted in prevention of osteo
phyte formation but also irnpaired cartilage repair
(Scharstuhi et al., 2002a). Thus TGF-f3 in moderation
may be useful for maintaining cartilage homeostasis
and in restoring proinflarnrnatory cytokine-stimulated
alterations in chondrocyte phenotype. However, this
factor bas also been shown to inhibit type II collagen
(the major cartilage collagen) gene in primary rabbit
chondrocytes by repressing the synthesis and activity of
Spi (Chadjichristos et al., 2002).
In surnmary, based on our resuits, we propose that
TGF-[3 activates ERK-MAPK pathway, which in turn
couid increase Spi phosphorylation anci its DNA bind
ing activity leading to TIMP-3 induction. Overexpres
sion of TIMP-3 in response to TGF-[3 could potentially
reduce TACE activity and dirninish TNF-c.t-driven
inflammation in joints. This signaling cascade may have
a pivotal role in the maintenance of chondrocyte dif
ferentiation, increased survival and their proliferation,
the features highly desirable fbr maintaining the in
tegrity of cartilage.
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Al)Stract
Transforming rowth faclor beta (TGF-b 1) induces cartilage extraceilular matrix synthesis and tissue inhibitor ofmetaIioproteinascs-3 (TIIvIP-3). an
important natumi inhibitor ofmatrix metalloproteinases. aecrecanases and TNF—aipha—converting enzyme. which arc implicateci in cartilage degradation
and joint inflammation. This study testcd the hypothesis that Akt/piotcin kinase B signaling pathway couid mediate TGF—f 1 induction ofT1MP-3 in
human articular chondrocytes. TGF—j activated phosphotylation of Akf in a cieiayed and sustained fashinn that correiated with TIMP—3 rnRNA
induction. Phosphaticlylinositol kinase (PI3K) inhibitors. Wortmannin and LY294002 and Akt inhibitor (NL—7 I—101) signiflcantiy inhibitcd TGF—V,—
induced Akt phosphorylalion. TTM?-3 expression. TTMP-3 promoter (—940 to +376)-dmen luciferase activity and Spi transcription faclor bindmg.
P13]( p35. AkI and Spi smail interfering RNA (5iRNA)-drivcn knockdown ofthe respective geneproducts signiflcantiy suppressed TGF-[-induccd
TFMP-3 gene expression. TGF-b-stimutated phosphorylation ofp70S6 Kinase and TIMP-3 protcin induction svas inhibited by rapamcin. Thus TGF-{’,
induces T1MP—3 gene expression in hutnan ehondrocytes partiy through Pl3KlAktpathway and Spi transcription factorand by transiationai rnechantsms
via mammalian target ofrapamycin (mTOR) signaling. TGF-j induction ofpro-survivai Akt cascade and TIMP-3 may be reiated 10 strengthening of
cartilage extraceflular matrix, increased ehondroeyte viability and maintenance ofjotnt tissue integdty.
2007 Elsevier inc. Ail rights reserved.
Ketiiords: Arthritis: Cartilaoc; Transforming growth frctor bela; Signal transduction; Akt; Transcription factors; TIMP—3; Gene reguiation
1. Introduction
A hallmark of rheumafoid arthritis (RA) and osteoarthritis
(OA) is resorption of cartilage extraeeliular matrix (ECM). This
is partly due to impaired endogenous repair proces.ses indueed
h an imbalance between anaboiic growth factors and eafabohe
proinflainmatory cytokines. intericukin— I (IL— I), IL—17 and
tumor necrosis factor (TNf-a), which inhibit the ECM
synthesis and induce matrix metalioproteinases (MMPs)
production [1,2]. Adult cartilage bas lirnitcd capacity to
rcgencratc and transfonning growth factor beta (TGF-[) farnily
* ColTesponding author. K-5255 Maillons, Hôpital Notre-Dame dti CHUM.
lSht) Shcrbrooke est. Montrdal. Quéhcc, Canada H2L 4M1. Tel.: ‘ t 514 590
3000x25690; lhx: -l 514 412 7612.
0898-6563/8 - sec front malter 2007 Elscvier Inc. Ail rights re’,erscd.
dol: If). I t) 6 j.cclisig.2007 1)2.1)07
members have the potential f0 stimulate its repair. Human OA
cartilage rcsponds poorl to TGF- due to decreased receptor II
[3]. Inhibition ofendogenous TGF- causes irnpaired cartilage
repair and excessive TGF-j leacis to the formation of
osteophytes in OA [4]. TOF-j, a multi-fiinctional factor
prodtteecl by monocytes macrophages, platelets and chondro
cytes. induecs chondrogenesis and ECM synthcsis [5]. TGF-18 I
is elevatcd in human RA synovial fluid and tissue, has
imlrntnosuppressive properties, [6] and is a major growth ftictor
for maintaining chondrocyte phenotype and homeostasis [7]. 11
suppresses inflaminatoty ccli infiltration, pannus formation and
joint erosion during acute and chronic arthritis by counteracting
the effects of IL-l [8].
MMPs and aggrecanases (ADAMTS. a disintegrin and
metatloproteinase with thrombospondin motif) digest major
cartilage ECM components including type II collagcn and
aggrecan as wcII as severai non-ECM substratcs during physi
ological and pathologicai remodeling [9.10]. Tissue inhibitors
ELSEWER
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0f metalloproteinases (TTMPs) arc 4 naturai inhibitors ofMMPs
with growth prornoting, pro-apoptotic, anti-apoptotic and anti
angioizenic ftinctions [il, 12]. Excessive MMPs and ADAMTSs
over TIMPs cause ioss ofarticular cartilage. TGF-[3 inhibits thc
expression of most M\-JPs but induces T1MP-1 and T[MP-3 in
ehondrocytes [7]. T1MP-3 is uniquciy iocatcd in ECM where its
N—terminal domain binds to chondroitin— and heparan sulfate
[13] and aise inhibits MM?-13, ADAMTS4 and ADAMTS5,
the principal cartilagc-degrading enzymes [14,15]. It blocks
aggrecan clegradation in cartilage expiants [16] and inhibits pro
ïnflammatory, TNf-a converting enzyme (TACE/ADAM- 17)
activity [17]. TIMP-3 can thus reduce inflammation in arthritis.
TIMP-3 inhibits angiogenesis by blocking the binding ofVEGF
te its reccptor and couid reduce rhcumatoid pannus fomia
tien [rcviewed in [1)]]. Such unique features make TIMP-3 a
potentiallythcrapcutic protein in arthritis [11,17]. Indeed, TIMP-3
overexpression in proliferating rhcumatoid synovial fibroblasts
induces apoptosis [18] ancl prevcnts invasion of cartilage by
pannus [19]. TIMP-3 knockout rnicc display an increascd initiai
inflammation and serum TNf-a level in antigen-induceci ar
thritis, supporting its protective ftinction against inflarnmatory
aflhritis [20]. In other systems, TGF-1 binding to ccli surface
associates types I and 11 receptors leading to phosphoiylation
of type T receptor kinase domain, transmission of signai via
stirnulatoty Srnads and transcription of the target genes [2 1].
In chondiocytes. Smad, PKA, PKC and Wnt pathways arc in
duccd by TGF-i relative to varions cartilage funetions [22]. We
prcviousiy showed the involvement cf Smad anci extraceilular
signal-rcguiatcd kinase (ERK 1 /2)-mitogcn-activatcd protein
pathways in TGF-.-induccd TIMP-3 in chondrocytes [23.24],
however, role ofphosphoinositide 3-kinase (PI3K!Akt) pathway
and its target transcription factors irnplicated in this induction
are unknown. PI3K-Akt’protein kinase B (PKB) pathway is
stimuiated by insulin-like growth factor leading to ccli prolif
eration, survivai and inhibition ofapoptosis [25]. Although P13 K!
Aki pathway is activated by TGE-) in human rhcurnatoid sy
novial fibroblasts in association with their prohfcration [26],
its role in chondrocytes and regulation of specific genes is net
known. 1-lere, we show the prcviousiy unknown and criti
cal role of PI3K!Akt pathway and Spi transcription factor
in TGF-5-stimulated increase cf TlMP-3 in human knee ar
ticular choncirocytes.
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2. Materials and methods
2. I. Ctiittirc’ ojchondrocvtes anti treatrnents
Tise normai human knee aiticular chondrocvtes (Cambrex; Walkerviiie, MD)
were grown to confluence as high-density passage 2 monolayer cultures in
Diflbnsntiation Bullekit medium For maintaining their dilfercntiated phenotype
(Canibrex). These cclls do not express type I colingen but express type ii coliagen, a
rnarkerofdi[ierentiated chondrocytes as determined by Nordwrn and Western blot
analysis (Fig. lA). Aber trvpsinizution, the cclls were grown in 6-well plates in
Otilbecco’s moditied Eaglc’s medium (DMEM) (Inviuogcn Lite Sciences Inc.
Burhngton. ON) wmth 10% feuil calf sertira fFCS). Ceils were washed with
phosphate buffered saline (PBS) and kept in sernm-frce DMFM for 24 h. P0
Kmnwse-spccitic inhibitors. Worussannin [27]. LY294002 (2-(4-Morphoiinyi)-8-
phenvl-4t1-l-benzopyran-4-one) [28] soU Akt-speciflc inltibitor, NL-71-lOl [29]
frais, Caibiochem (La JoUa, Ci\) werc dissolvcd in dimethyl sulfoxide (DM50)
ancl added in thc saine medium at the concentration of 10—20 iM respectively
30 min hcfore O’eatmcnt with hurnan platelet TGF—fl 1 (10 ng/rnl) fR&D systems,
Minneapolis, MN) kw 24 h. In some cases, rapamycin dissolved in DMSO ssas
added at 20 and 100 ng/rnl concentmtions t h pdor to TGF—fl trealment for 24 h.
TGF-iS I was reconstituted in 0.1% fraction V ot bovine serum albumin (OSA)
(Sinsa) aoct 4 mM OCI as rccotumcndcd.
2,2. RIVA extraction anti Northern hytritiization analvsis
Total RNA ssas extnicted hy a rapid pm’ocedure [30] and aliquots of 5 pg
analyzed by electrophoretic inmctionation in 1.2% formaldehyde-agarose gels. Tise
RNA was elcctroblotted onto Zetaprobe nylon mensbranc (Bio-Rad, Mississauga.
ON) usilsg a Bio-Rad Tramssbiot in tise presenee of iX TAE butTer at a carment of
40 mA ovcmight. Northcrn blots were hybddized with a hurnan TIMP—3 [31) RNA
probe made with T3 pcilymcrase frotis plasrnid pBltmeSeript. Tise banian 285
rihc,somaal RNA p(asmnid (lions ATCC. Maisassas. VA) was digestcd with Xhai and
a probe synthesized usingT7 poiynsernse. The type li collagen (kindly provided by
Dc Fera Vtiorio, Tucku. Finlanci) RNA prcsbe svaa made with SP6 polynserase. Ail
probes wcre labeled ta higis-specific activity (I x i05 cprn/gg) with [rs-”2P] CTP
(300(1 Ci/mmoi, Perkin filmer Canada Toc, \Voodhridge. ON) witb tise RNA
laheling kit frans Protisega Biotech (Madison. tvi) aecording ta their pratocols.
2.3. Ïf’sie,ui hiot anu/iwis
Type Il and type I eollagen nihbit polyclonai antibodies (#2341 87 and
234168, Calbiochcm) were tised ta monitor the phenotype ofchomsdrocytes. P13
kiisase p85 (Cat ira. 4292) (Ccli Signahing) antibody svas used ta vedfv knock
clown bv siRNA. The activation ofAkt kiisase sVas analyzcd bv Western imnsu—
noh tottiisg using monoclonal antihocly against Phospho—A kt Ser4 73 or with
polyclonal antibody against aIl Aktproteins in rabbit (Ccli Signaling Teehttoiogy,
Beverley. MA). Ais anti-phospho-p70 S6 kinase (Thr) rabhitpolveional 1gO (Ccii
Signating) was tmsed 10 anaiyzc tise extracts treateci with rspamyein. Anti-S1, I
rahbit polycional antihody (Active Motif Carlshad, CA) was uscd to verify
kncickdciwn hy RNA iistcrference. For T1MP-3 protein ievets. total celtular
extraets from human chondrocytes (10 -20 (5g) were stmbjected b fractionation by
u 15% SDS-PAGE mini gel (i3io-Rad system). transferrcd ta PVDI’ (Pail
Corporation. Anne arbor, Mi) by cleetrohlotting and reaetcd with the 1:400
dilution of hurnan T1MP—3 polyclonal antihodv (Chemniccmn International,
Temeeuia, CA). Siihsequently, ntemnhranes werc ineubated svith tise anti-rabbit
secondaiy isorseradish pemoxidase-conjugated antibody (Promega, Madisoms tVl)
antI tise TIMP—3 protein hands revealec( with the chensilurninescence deteetion
systeni ofRcsehe Biochemicals ([aval. QC) svith theirprotocols. Contrai proteins
that served as loading eomstrol were unaffeeted proteins flom tise Western blots of
saine ecliular extracts. In somne cases, Western hlcrts wcme reprobed svifls nsono
clonai anti bela aetims antihody (Sigma). Prctein and RNA hands from multiple
ocre scatsned hy using Alpha Imager 2000 (Alpha lnnotcch Corporation).
The reeorded densitometrie values ocre eonverted mb pereentage values and
prcsented as bar graphs usimsg GraplsPad Prism3 software (San Diego, CA).
2.4. Titras je,tt trmatsfectio,ts
Cefls ocre transfected svith PT3K pXScs SMARTpo01 and contrai s1RNA
(Dharnsaeois. ine./Upstate Catalog 4 M-003020 anti D-001206-13-05 respee
tiveiy) or Akt 5iRNA and ils negative coistrol (SignaiSilcisce Akt siRNA kit, Ccli
Signaling #6210) or SpI Validated Steaith RNAi DuoPak and its rnedium-GC
content siRNA contrai (Invitrogen #t2936-62, 12935-300 via calcium
phosphate precipitation method for adiserent ceils ils suspension as folIows.
Celis were detached by trypsinizalion. tmypsims removed hy eentrifùgation and
2.5 < i0 ccli suspension aliquots ineubuted with 70 il siRNA (200—250 nM)
calcium phosphate preeipitate bar 25 min with gentle roeking every 5 mm, I ml
of 10% FCS-DMEM added anti pIated in sertms-containing medium for 3—4hi
37 C for adherenee. Medium svas rernoved. celis washecl with POS. allaweci
them 10 reeo’.er for 24 h, maintained in scrum-free medium for 24 Is and then
sliiisuiated with TGF—f for 24 h. Duc ta absence of matrix during transldctiois in
suspeiscled chondrocytes. this metlsod resuils in 80% transflction efflcieney as
detennined with a fluorescent double-stranded RNA oligonucieotide. Equai
arnount (20 tg) ofprotein nus analyzcd far nseasurilsg TIMP-3 protein levets as
above. In otiser experiissents. 2 pg ofTIMP-3 promoter Iticiferase (—94010±376
region) [32], eytonsegalovirus (CMV)4?t’nilla lueiferase (0.2 gg, tramssfection
contrai) sud Akt siRNA (200 nM) were cotransOcted by the modifled caleiuns
pisospisate procecitire deseribed above and aber recoveiy. treated witis iishibitors
or stinsulated with TGF—t antI luciferase aetivity measured with Prornega Dual
Luciferase Reporter assay Svstemn and Turner Designs Luiuumiouneter TD-20’2ft
aceoiding ta their recoinisseiided proeedures.
2.5. Meastm,e,nent o/Spl trunscriptioo fctclor mtctivities
Human knec chondrocytcs were cilher transfected with Akt siRNA or
preheated with ditlereist PI3K/Akt inhihitors antI stimuiated with TGF-) for
24 h. Nticlear protcins were exlructcd as dcscflhed [33]. Equal sumotmnts of
nueiear extracts (10 gg) were used ta measure SpI aetivity by using TransAM
kit (Active Matif Carlsbad, CA), wisicis is an ELISA-hiised ealorimetric assay
for nseastinng lise hindimsg of transcription factors wilh tiseir conseissus sites.
Aber iiscubatmon ofextraecs with insusscsbilized S1, I coissensus DNA for I li, anti—
SpI antibody was added for I h followed by incubation with HRP conjugated
anti IgG, color developrnent. sttsppage of color developmnent and measureinent
at 0D450 by Fluastar Optima ELISA reader (BMG [ah Technologies).
Ail the experiments were perfornied al least 3 times antI the resuits svere
reprodueihie.
3. Results
3. 1. hithiction o/ AItt piiosphort’Iation anti TJl’1P-3 niRNA by
TGf—f31 lit ttuman artict,ictr cÏtoitdioci’tes
We first cxarnined thc differentiatcd phenotype of httrnan
chondrocytes under our experirnental conditions. As deterrnined
by Western blotting. these ceils at passage 3 do flot express
115 kDa type coliagen baud but do express high leveis of
Col lagen If tuRNA and 100—210 kDa type Il collagen bauds, a
chondrocyte-specific rnarker (Fig. lA). To examine if TGf-[3l
stirnulates Akt phosphoiylation in hurnan chondrocytes, quies—
cent ceils wcre exposed to this factor for cliffercut timc periods.
TGf-[ induced Alct phosphotylati on abeve basal icueis at 4 h that
rernained ctcvatcd ttp to 24 h without affecting thc total Akt Ievcis
(f ig. lB and C). TTMP-3 rnRNAvas aise concornitantiy induced
by 4 h that continued to increase up to 24 h. The leveis of2XS
rRNA that seived as loading contre! rernained constant (Fig. I D).
To explore the rnechauisrn ofthis regulation, we flrst tested
the ability ofdifferent PI3K and Akt phai-macological inhibitors
to suppress the downstrcarn Akt phosphotyiation in httman
chondrocytes. ERK pathway inhibitor, PD98059 had no effect
while ail PI3K (Wortrnannin, LY294002) and Akt (NL-71-l01)
inhibitors at 10 11M concentration signiticantly down-reguiatcd
TGf-j31-inducecl Akt phosphoryiation dernonstrating thcir
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Fig 2. P13 kinase inhibitors. Wodmannin, LY294002 and P13K siRNA inhihit TGF-l-induced TIMP-3 gene expression in human articular chondrocytes. Quiescent
and coniluent chondrocytes were either treated with vehicle (DM80 and PBS with 0.1% BSA and 4 mM 1-ICI) as eontrol or pretreated with 10 or 20 (LM of
A) Wortmannin B) LY294002 C) Or transfected with negativc contro] siRNA ami PI3K p85n SMARTpo0I siRNA alone for 30 min anti then stimulated with TGF-)
for 24 h. in A and B. upper two panels are TIMP-3 anti 28S rRNA Northern blots and two lower panels tepresent TIMP-3 protein Western blot and control protein
sewinu as loading control. Tise two TIMP-3 hands represent glyeosylated (upper) and unglycosylatecl (lower) forrns ofTIMP-3 protein. in C, levcls ofT1MP-3 and
PI3K p85 proteins mcasttred hy Western blotting arc shown. Graphs A and B show densitometrie normaIized values ofTlMP—3 protein anti RNA in percentage whert
as graph C shows T1MP-3 protein and p85 P13K. Data are presented as the niean± SEM ofthree independent experiments. P<0.05 was considercd significani.
spccificity (fig. I E). These and other inhibitors werc used in the
subsequent studios.
3.2. Suppression of TIMP—3 induction he phosphatidvtinositoi
kinase (PI3K] inhihitors anti s1RNA
To investigate ifPI3K is involved in TGF--induced TIMP-3
gene expression, human chondrocytes were pretreated with the
inhibitor of P13 kinase, Wortmannin or relatively more specific
inhibitor, LY294002 for 1 h and then stimulated with TGF-[, for
24 h. Both agents (fig. 2A and B) partially or complctely
inhibited TGf-[3-induced TJMP-3 mRNA and protein expres
sion without aflecting the constant levels of28S dbosornal RNA
ami unrelated control proteins.
To fttrther verify these resuits by genetic means, chondrocytes
were transfected with p85a PI3K siRNA and negative control
siRNA. Afler transfection and recovery, chondrocytes were
stimulated with TGF-[3> for 24 h and endogenous PI3K p85
(regulatory tmit) and TÎMP-3 protein levels analyzed. Negative
control siRNA did flot affect PÏ3K p85 levels and TGF-[
enhanced TIMP-3 protein expression while P13K-spccific siRNA
suppressed expression of both proteins. The levels of control
protein remained constant (f ig. 2C). None ofthe above inhibitors
or siRNAs significantly affected the viability of chondrocytes
(rest.ilts flot shown).
3.3. Inhibition of TGF-/3-induced TfMP3 expression by ,4kt/
PKB inhihitor and ,4kt siRN4
We subscquently invcstigated the role of Akt in TGf-
induced TIMP-3 increase by pretreating the chondrocytes with
the specific pharmacological inhibitor of Akt, NL-7 1-101 (sec
above) and stirnulating with TGf-[t. NL-71-101 diminished
TIMP-3 rnRNA and protein induction by TGf-h without
affecting the levels ofcontrol RNA and protein (Fig. 3A).
To further evaluate the validity of these resuits by genetic
tools. chondrocytes were transfected with negative control
siRNA and Akt-specific siRNA [34] and thon stirnulated with
TGF-13. Negative control siRNA had no effectwhile Akt siRNA
transfection drastically knocked dowu Akt protein levels and
induction of TIMP-3 protein by TGf-f%. The levels of p42
MAPK protein that served as loading control did not change
(Fig. 3B). These doses of inhibitor or siRNAs did flot
signiflcantly affect the viability of chondrocytes (flot shown).
3.4. influence of P13 kinase inhibitors anti Akt s1RNA on
human TJA’!P—3 promoter actit’ity
To investigate the mechanisrn ofPI3/Akt modulatcd TIMP-3
gene expression, 5’-flanking region (—940 to +376) ofhuman
TIMP-3 promoter placed upstream of luciferase gene [32] along
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Fig. 3. Akt inhihitor, NL-71-l0l and Akt siRNA inhibit TGF-lx-iitdueecl TIMP-3 gene expression in hurnan aifieular chondrocytes. A) Qtncscent chondrocytes wcrc
cither lrcaled with vchicles aS control or pretreatcd with 5 or 10 [tM ofNL—7 I—101 alone for 30 min and then stimulated with TGF—jt (or 24 h. Upper two panels depiel
TIMP-3 and 28S rRNA Northern blots and two lower panels represent TIMP-3 protein Western blot and control protein sewing as unaffèeted loading control. The two
TIMP-3 hands represent glycosylated (upper) ancl unglycosylated (lower) fonris ofTlMP-3 protein. B) Knee chondrocytes were either treatecl with vehicles (Control)
or transtdcted wilh 200 nM of negative control or Akt srnall intcrferin RNA (s1RNA) and then exposed to TGF- for 24 h. The panels represent TIMP-3 protein
Western llot (upper) and total Akt conirol proten (nOdUle) and p42 MAPK serring as unaffected loading ccmtrol (lower). Graph A shows densiiometrie nornialized
values of TIMP-3 protein and mRNA in percentage whcre as graph B shows TIMP-3 protein and total AKT. Data are presented as the rnean*SEM oC three
independent experiments. P<0.05 svas considered significant.
with a CMV-drivcn Renifla iLtciferasc-driven x’ector or Akt
siRNA vas iransfccted in hurnan knec chondrocytes. After
rccoverv and confluent growth, cclis were also treatcd with
PI3K inhibitors and thon stirncilated with TGF-[. Analysis of
luciferase activity revealed induction of TIMP-3 prornoter by
TGf- that was inhibited by Wortmannin, LY294002 and
transfection of Akt siRNA, suggesting the role of promoter
elements in PI3K/Akt-mediated TIMP-3 induction (Fig. 4).
jig htvolveinent of Spi ttctttscrtptio!i Jiictor in TR’fP—3
induction anci decrease in TGf—/3—inducecÏ Spi binding cictii’itv
nM bj’ P13 kinase inhihitors and Akt siRyVA
1-lurnan TIMP-3 promoter contains 4 Spi binding sites t32,35].
We have previously shown that Spi overexpression and phar
rnacological/antisense inhibition respectiveiy increases or sup-
presses TIMP-3 gene induction 24]. To further explore the
importance ofSp 1 in T[MP-3 induction, Spi levels were knocked
down by RNA interference with Spi siRNA (Fig. 5A, middlc
panel). Negative control siRNA did not inhibit Spi expression.
Spi siRNA transfection draslicaiiy redtlced the TGF- induction
of TIMP-3 (Fig. 5A, upper panel) and did not afli.ct beta actin
leveis (Fig. 5A, lower panel). Viabiiity of chondrocytes was not
affected significantly by these treatmcnts (flot shown).
A
—* 28 S rRNA
- : TIMP-3 protein
—
Controiprotein
111 TIMP-3protoin
N TIMP-3 RNA
TIMP-3 Protein
Totat AKT
DIII
= o i= =, o
zz
o
I-
j
z
IL
ta
I-
Z
w
o
ha
_J C)
[s
o
o
s
pTIMP3 Promoter lue 2 2 2
pRL-CMV veclor (R lue) .2 .2 .2
AkI OIRNA 0 0 0
TGF.)t - *
Wortmannin
LV294002
2 2 2 2 2
.2 .2 .2 .2 .2
0 0 0 200 200
+ - * -
+ S - -
-
- + +
* tOng/mt
10 1iM
10 pM
Fig. 4. PI3K!Akt inhihitors and Akt s1RNA down-regulate human TIMP-3
ptotnoter-luciferase activity in htitnan chondrocytes. Htiman knee chondrocytes
svcte transiently eott-ans(octcd with 2 pg of hum:tn TIMP—3 promotcr—fltefly
luciferase vector. 0.2 tg of a plasrnid cxpressing Rcnilta Iucit’erase (internat
control) and 200 nM Akt siRNA as indicated. In other cases, cells wetc treated
with Wotlmanntn. LY294002 alone or wtth TGF-)’, for 24 h. Extracts svo-e
analy7ed for luciferase activity. The values of flrcfly luciferase to l?enilla
lucifetase ratios wcle plotted with Prism 3.0 software. Data are prescnted as the
mean±-SEM tif three independent expertments. P0005 was considered
signilicani.
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Fig. 5. A) Spi knockdowit with Spi smaii inteiferenec RNA (siRNA) inhibits TGF-(-indticed T!MP-3 gene expression in hutnan artieniar chondrocytes. Quies
cent
chondrocytes wctc cither treatcd with vehicics (Contrai) or ti’ansteetcd with 25f) nM ofncgative contro] or Spi sIRNA and then exposcd ta TGF—(’ for 24h. The ptneis
represcut TiMP-3 protein Western biot (upper), total Spi protein (middie) and beta actin servina as unaflècted ioading controi (iower). The graph shows densitometric,
itorniaiized vaines of TIMP-3 protein and SPi in percentagc. Data are presented as the mean±SEM of three indepetident experiments.
P<O.05 svas considered
signiticant. R) Fffect ef Wortrnanuin, NL-7i-ifli. LY294002 and AktsiRNA on Spi activity in chondrocytes. The human knee chondrocytes werc trcatcd as indicated
and eqtial ainount at nucicar extracts were assayed for Spi actisity by using TransAM Spi Kit with an ELiSA reader. Data arc piesen
ted as the opticai density
(CD 450) meaniSEM vaines of three independent experirnents. P<O.05 vas considered significant,
Due to the importance of Spi in human TIMP-3 regulation,
we explored if this transcription factor may be a possible target
of PI3KJAkI pathway. To this cnd. wc transfccted hurnan knee
chondrocytes with Akt siRNA ortreated with differentinhibitors
foiiowed by stimulation with TGf-. Spi binding activity from
nuclear extracts was monitored with an 5pi transcription factor
ELISA. TGF-b increased Spi activity and pharmacological
inhibitors as wcil as Akt siRNA signiflcantiy dirninished binding
of Spi wïth its consensus sequence (Fig. 53).
3.6. Dou’n—regulation of TGF—f3—induced p70$6 kinase ami
TIAfP—3 by rapcunvcin
Since AkUPKB pathway stimuiates multiple downstream
signaling events, we investigated whether TIMP-3 induction is
sensitive to rapamycin and is modulated by mammalian target
of raparnycin (rnTOR) [36] and p7OS6K. TGf- cnhanced the
phosphoiyiation ofp7OS6K and indttced TIMP-3 protein ievels
while rapamycin (20—100 ngirnl) dose depcndently reduced
expression of thesc protcins. The control beta actin lcvels
rcrnained rclatively constant. 1-Iowever, rapamycin did not
diminish thc induction of TIMP-3 RNA expression (Fig. 6A).
4. Discussion
TGf- is an important plciotropic factor involvcd in
chondrogenesis, cartilage repair and matrix synthesis. Due to
the versatile abihty of T1MP-3 to inhibit cartilage-degrading
MMPs and ADAMTS, and TNf-a-activating ADAM-17, it is
an important therapeutic protein for arthritis. We have shown
here for the flrst finie by severai phannacoiogicai and genctic
approaches that PT3IVAkt pathway mediates TGF--induced
TIMP-3 gene expression prirnarily at the promoter levcl via Spi
transcription factor activity. We further dernonstrate that
downstrcam ofAkt, TIMP-3 is also regctlated at the translation
level via mammalian target of rapamycin.
Time-course studies demonstrated that TGF-Ç3 does flot
induce Akt phosphoryiation rapidly but in a rather deiayed
fashion after 4 h. This is in contrast with Smad2 and ERK
phosphotylation that is induced by TGF-l3 rapidly within
20 min to I h [23.24]. This suggests eariy events such as cross
taik with other pathways or interniediate factors. Howcver,
TGF- did not induce insulin-like growth factor (TGF-l) at any
time point bctween 20 min to 24 h and IGF-1 also did not
enhance TIMP-3 expression at variotis doses. FuChermore,
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ERKII2 Akt r— NL-71-10i, Akt s1RNA
\ mTOR H— Rapamycin
p70 S8 kinase
(] j] F-j-—Sol siRNA
TIMP-3 transcriptional indudH TIMP-3 rnRNA translation
Possible Increased chondrocyte survival, decreased cartilage degradation and
stronger extracellular matrlx
Fig. 6, A) Rapamycin down-regulates TGF-b-indueed phosphotylation of p70S6 kinase and TIMP-3 protein but flot its RNA expression in htiman aieuiar
chondrocytcs. Quiescentchondrocytes were cither treated with vehicle (DMSO and PBS with 0.1% ESA and 4 mM HCI) as contrai or prclreatedwith 20 or 100 ng/ml
of rapamycin alone for I h and then stimuiated with TGF-( for 24 h. The upper three panels depict phosphorylateci p7OS6 kinase. TIMP-3 protein ancl beta actin
Western blots. The osxer Iwo panels are TIMP-3 Northem blot and 2XS ribosomal RNA badina control. B) Ptoposed modcl for TIMP-3 induction by TGF-j via
activation of PI3KJAkt and ERK pathways. ‘flic activation steps are indicated by arrows, svhieh could cuirninatc in incrcased chondrocyte surv
ivai and strongcr
cxtracclluiar mas ix. lite inhibitot’s sxhiclt dosvit-rcgulale TTMP—3 mRNA or protcin expression are also dcpictccl. mIOR. mamrnaiian targcl ni’
transcription. The
moUd Unes flot ruic oui the possible cross talk between the two patlisviys. Spi and CCAATlenliancer hinding protein (C!EBP) sites in the human TIMP-3 proiootcr and
transcription initiation site (41) are aiso sbown.
IGF- receptor blockade did flot affect induction of TIMP-3 by
TGF-[. Thus TGF- effects do flot SCCH1 to bc rnediated by
IGf-l (rcsults not shown). TIMP-3 and TGF- arc multi
lunctional proteins. Both bave becn shown to induce apoptosis
in diftbrcnt ecu—types [37]. In contrast with these observations,
stirnttlation of PI3K!Akt by TGf-5 in chondrocytes dcmon
stratcd here suggcsts a pro-survival rote for this factor in chou
drocytes. Ïndeed, TGF-[’ is considered as e cartilage growth
prornoting factor [5]. It bas been shown that binding of Akt with
nonphosphorylated Smad3 blocks TGf-[-induced Smad3
phosphorylation, its interaction with Srnad4, nuclear trausloca
tion and apoptosis in certain celi-types t3] Howevcr, in chon
drocytes, TGF--stimulated Smad2 and ERK phosphotylation
is followed by Akt phosphorviation and these pathways or
their interactions arc necdcd for TIMP—3 induction [this work,
[23.24]]. Treatmeut of porcine chondrocytes with N-terminal
human TIMP-3 did not show any significant apoptosis [16].
Similariy, TIMP-3 may also be anti-apoptotic, as knockout of
this gene results in increased apoptosis in mammaty gland [39].
This is fttrther supported by another snidy where TIMP-3
prornoted proli feration of non—transforrned cet Is under low
semm condition [40]. TIMP-l bas also been shown to indncc
cdl survival by PI3K]Akt pathway [41]. Whether these ap
parently paradoxical rcsults are due to diffcrences in endoge
nous and exogcnous TIMP-3 expression levels. remains to
be studicd ftnlhcr. It is possible that physiological icvcis of
TIMP-3 promote survival and ectopic overexpression at non
physiological levels induces apoptosis.
Concomitant induction of Akt phosphotylation and TIMP-3
suggests direct coirclation betwccn the two events as demon
strated by subsequent cxperimcnts. Inhibition ofTIMP-3 mRNA
and protein by two diffcrent phamiacological PI3K inhibitors and
siRNA strongly support the rob of PI3K in TIMP-3 induction.
Similarly, suppression of TGF--induced TIMP-3 rnRNA and
protein expressiot’t by AktJPKB inhibitor and Akt siRNA
reinforces the involvernent of Akt/PKB in TGF-[ signal
transduction leading to TIMP-3 induction. Based upon inhibition
by Wortmannin and LY294002, P13 KIAkt pathway requircment
was shown in IGF-l-induced proteoglycan synthesis [42]. 11 is
likely that scveral growth factors utilize this pathway 10 promote
ECM synthcsis, growth and sttrvival. TIIvIP-3 prornotcr-repOter
transfection studies suggest that the 5’ flanking rcgion spanning
—940 to +376 contains most of the TGE--responsive seqtlences.
This is in agreement with a previous stttdy where region from
—463 to + I was shown to be responsible for senttn-stinmlated ccli
cycle progression; senim contains e heterogeneous mixture of
growth factols [35]. It lias becn previously shown that TIMP-3 isa
cell cycle-rcgulated genc [43]. Mimicty of cxogcnous TIMP-3
prornoter regulation with that of endogcnotis TIMP-3 genc
suggests that inhibition most likely takes place at the transcription
level. Inhibition ofTllvIP-3 prornotcr-drivcn luciferase activity by
the pharmacologie inhibitors and Akt siRNA also supports the
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notion that this prornoter rcgion may be the target of TGf-V
stimulated PI3KJAkt pathway. Hurnan TIMP-3 promoter has
several putative transcription factor binding sites that may be the
targets ofthis cascade. It has 4 SpI binding sites hetween —112 ta
± I region [35], which are important mediators of TIMP-3
expression [24]. The latter resuits were rcconfimicd hcrc by thc
newiy developed RNA interference-mediated Spi knockdown
approaches. Incrcascd Spi activity by TGF-15 anti its dccrcase by
the inhibitors and Akt siRNA furthcr support Spi as a possible
target ofAkt pathway. Spi is a pivotai factor for the expression of
various genes related ta ECM synthesis, cell cycle and growth
[44.45]. In other systems, increased expression of vascular
endothelial growth factor by Akt required Spi as demonstrated by
Sp siRNA-driven knockdown [46]. Simiiarly. a geuc anay
profiling study showed Spi binding site in the prornoter ofFra-]
gene as the target ofPI3K pathway activation [47]. Other potential
targets include CCAAT enhancer binding protcïn (C/EBP) site at
—40 region ofhurnan TTMP-3 prornoter.
Multiple targets downstream ofAkt/PKB invoived in growth,
proliferation, survival and protein synthesis are activated.
Phosphorylation ofp7OS6 kinase by TGF-b and its dose-depen
dent inhibition by rapamycin suggest that TIMP-3 induction
occurs in part via mTOR and p70S6 kinase. This mechanism
appeared ta be specifie, as the levels of(-actin were not affected.
Since this pathway is involved in ccli growth, survival. mRNA
translation and ribosorne biogencsis [48], TIMP-3 protein
inhibition may be duc ta dccrcase in its translation by raparnycin
as this dmg did flot affect TIIvIP-3 rnRNA induction levais.
Alternatively, rapamycm may inhibit ccli cycle-regulated TIMP-3
by interfenng with cell-cycle progression. These resuits also
suggest TfTvlP-3 as a target of this immunosuppressant dnig.
Ïnterestingly, lGf-i -induccd proteoglycan synthesis in chondro—
cytes is also inhibited by raparnycin possibiy at thc translation
level [42].
5. Conclusions
In conclusion. TGF-l5 1 could exert its growth-promoting
effects on chondrocytes by activating P13 kinase/Akt pathway and
TIMP-3 expression, which by bincling ta heparan sulfate and
chondroitin sulfate may resuit in strengthening ofcartilage ECM,
incrèased chondrocyte viabiiity and maintenance ofjoint tissue
integrity (Fig. 6B). The abilities ofT1MP-3 ta black MMP and
ADAMTS activities could bc an added benefit. tt is aiso
interesting to note that in contrast with thc ccli prohferation anti
survivai-associated PI3KŒ anti [3 isoforrns. knockout and specific
pharmacological inhibition of PI3K-y isofonu bas recently bcen
shown to reduce bath synovial inflammation and cartiinge erosion
in RA-like mouse models [49]. Thus, specific isofornis of this
pathway have different ftmctions and can be targeted for reducing
inflammation or enhancing survival. Finiher, observed suppres
sion of arthritic inflammation by TGF- could in part bc dite to
increased TIMP-3 and reduced TAOE and TNF-ee activities.
Thus, a better undcrstanding of the mechanisms of TIMP-3
induction by TGF-[$ can lead ta novel therapies for inhibiting
synovial hypcrplasia/inflamrnation and for stimulating cartilage
regeneration, the rtvo important goals in treating arthritis.
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ABSTRACT
Transforming growth factor beta (TGF-31) promotes cartilage extracellular
mati-ix synthesis and induces tissue inhibitor of metalloproteinases-3 (TEVW-3), a
natural inhibitor of mati-ix metalloproteinases, aggrecanases and tumor necrosis
factor alpha converting enzyme, which are implicated in articulai- cartilage
degradation and joint inflammation. TGF-31 activates Akt, ERK and Smad
paffiways in chondrocytes. However, specific i-ole of Smad pathway in TIIvIP-3
induction by TGF-31 lias not been investigated which was explored here by
pharmacological and genetic knockdown approaches. TGF-(31-enhanced Smad2
phosphorylation and TIMP-3 protein expression could be inhibited by the Smad2/3
phosphorylation inhibitors, PD169316 and SB203580 but flot by an inactive
homologue, $B202474. Similarly, Smad2-specific siRNA-driven Smad2
deficiency also down-regulated TINP-3 induction. Specific inhibitor of Smad3
(SIS3) and Smad3 siRNA abolished TGF-3 induction of TIMP-3 - Negative control
siRNAs had no effect. Smad2 and 3 siRNAs also down regulated TIMP-3
promoter-driven luciferase activities, suggesting transcriptional regulation. SiRNA
driven co-Smad4 knockdown abrogated TIMP-3 augmentation by TGF-i3. TIMP-3
promoter deletion analysis revealed that —$2$ deletion retains the original promoter
activity while —333 and —167 deletions display somewhat reduced activity
suggesting that most of the TGF-$-responsive, cis-acting elements are found in the
—333 fragment. Chromatin Immunoprecipitation (Ch]P) analysis confirmed binding
of Smad2 and Smad4 with the —940 and —333 promoter sequences. These resuits
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suggest that receptor-activated Smad2 and Smad3 and co-Smad4 mediate TGF-$
stimulated TEvIP-3 gene expression in human chondrocytes and T1MP-3 gene is a
target of Smad signaling pathway.
INTRODUCTION
Degradation of cartilage extracellular matrix (ECM) by proinflammatory
cytokine-stimulated matrix metalloproteinases (MMPs) and aggrecanases
(ADAMTS or A Dystrophin And Metalloproteinase with ThromboSpondin motif)
(1,2) is observed in inftammatory rheumatoid arthritis (RA) and aging-associated
osteoarthritis (OA), the most prominent forms of arthritis in clinic (3,4). Cartilage
from older patients has limited capacity to regenerate possibly due to reduced
transforming growth factor beta (TGF-t3), its type II receptor and resulting
chondrocyte hyporesponsiveness (5). TGf-t3 superfamily members stimulate
chondrogenesis during development and maintain cartilage integrity in adults (6,7).
In rat models, it suppresses acute and chronic arthritis by counteracting the effects
of the proinflammatory, interleukin-1 (IL-1) (8); an observation flot reproduced in
older mice (9). Elevated TGF-f3 levels in human rheumatoid synovial fluid
activates synovial fibroblasts, which ultimately invade and destroy cartilage (10-
12). Excessive TGF-f3 induces formation of joint outgrowths called osteophytes,
which limit joint movement and cause pain (13). Inhibition of endogenous TGF-13
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by scavenging type II receptor or by its signaling antagonist, Smad7, in a papain
induced murine arthritis model prevented osteophyte formation, synovial
thickening and impaired cartilage repair, suggesting its crucial role in these
pathological and physiological processes (14,15). In a rabbit model, TGF-t3 failed
to repair cartilage and induced adverse effects such as cartilage degradation,
muscle edema, fibrogenesis and chondrogenesis in synovial lining (16). Multiple
TGF-j3 injections into the murine knee joints induce OA-like changes in the
articular cartilage and surrounding tissue, suggesting a role of TGF-3 in OA (17).
Thus, in small amounts, TGF-f3 is implicated in suppression of arthritis and
cartilage remodeling. TGF-$1 is also a favorite stimulus for regenerating high
quality cartilage (18).
TGF-i3 exerts its effects by inducing multiple genes including tissue
inhibitor of metalloproteinase-3 (TIMP-3), a member of TIMP family of proteins
(19,20). TIMP-3 protein is uniquely located in ECM where its N- and C-terminal
domains (21) bind to chondroitin- and heparan sulfate (22). In cartilage explants,
TIMP-3 inhibits MMP-13 and ADAMTS4, the principal proteases causing collagen
and aggrecan degradation in arthritis (23-25). It also inhibits through different
mechanism (26), the TNF-a converting enzyme (TACE or ADAM-17) that
activates membrane-bound precursor of proarthritic cytokine, TNF-a into soluble
secreted form (27,28). Thus, TIMP-3 can regulate TNF-a-driven inflammation.
TIMP-3 knockout mice display an increased initial inflammation and TNF-a level
in antigen-induced inflammatory arthritis, supporting its protective function. These
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mice are more susceptible to age-dependent cartilage degradation (29,30). These
distinct features make TIMP-3 a potentially important therapeutic protein in
arthritis (31,32). Indeed, TIMP-3 overexpression prevents invasion of cartilage by
human rheumatoid synovial fibroblasts in a mouse model (33).
Due to therapeutic potential of TIMP-3, it is important to understand
mechanisms of TGF-t3 induction of TIMP-3. In other ceil types, TGF-f3 first binds
with type II receptors and then phosphorylates and activates type I receptor on
serine and threonine, leading to transcription of the target genes via stimulatory
Smad2/3 and co-Smad4 (34,35). Recently, T3RII-B a type II receptor variant was
found to complex with other TGF-f3 receptors such as betaglycan and endoglin to
enhance signal transduction (36). Smad2 and -3 are found in association with
proliferating and maturing chondrocytes respectively (37). Smad3 knockout mice
display QA-like symptoms (38). We previously showed Smad2 phosphorylation by
TGF-f3 in bovine and human chondrocytes (39). Subsequently, we demonstrated
the essential role of extracellular-signal-regulated kinase (ERK)-mitogen-activated
protein kinases (MAPK), PI3KJAkt pathway and Spi transcription factor in TGf
fl-induced TIMP-3 gene in chondrocytes (40,41). Here we show for the first time
that Smad pathway is critically involved in TGF-f3-enhanced T1MP-3 gene
expression.
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EXPERIMENTAL PROCEDURES
Ceil culture and treatments-Normal human knee chondrocytes (Cambrex,
Wallcerville, MD) were grown in Differentiation Bullekit medium as high-density
short-term monolayer cultures in 6-well plates up to passages 2 and 3. Under these
culture conditions, they continue to express collagen II, a differentiated
chondrocyte marker (41). following confluent growth, chondrocytes were
maintained in serum-deficient Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Life Sciences mc, Burlington, ON) for 24 h and subjected to different
treatments. In some cases, chondrocytes were pretreated in serum-ftee medium
with the Smad2/3 pharmacological inhibitors, PD169316, SB203580, SB202474 or
SIS3 (Calbiochem, La Jolla, CA) for 60 min and then stimulated with 10 ng/ml of
TGF-31 (R & D Systems, Minneapolis MN) for 20 min (for Smad
phosphorylation) or 24 h (for TIMP-3 protein expression). Control celis received
equivalent amounts of the vehicle, dimethyl sulfoxide (DMSO) and 0.1% fraction
V of bovine serum albumin (BSA) and 4 mM HC1.
Western blotting-Rabbit polyclonal anti-human antibodies for
phosphorylated Smad2 (#3 101 S) and Smad3 (#95 14S) and total Smad2 (#5 1-1300,
Zymed laboratories), Smad3 (#AB38 17, Chemicon International, Temecula, CA),
Smad4 (# 9515, Ceil Signaling Technology, Beverly MA, 1:400 dilution) and
Smad7 (H-79, Santa Cruz Bioteclmology Inc., Santa Cruz CA) were used as before
at dilutions (mostly 1:400) recommended by the manufacturers. for TTMP-3
protein levels, total cellular extracts from human chondrocytes (20-30 g) were
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fractionated by a 15% SDS-PAGE mini gel system (Bio-Rad Laboratories Canada
Ltd., Mississauga ON), transferred to PVDF (Pail Corporation, Anne arbor, MI) by
electroblotting and reacted with the 1:400 dilution of human TIIVIP-3 polyclonal
antibody (Chemicon International, Temecula, CA). Subsequently, membranes were
incubated with the anti-rabbit secondary horseradish peroxidase-conjugated
antibody (Promega, Madison WI) and the TEVIP-3 protein bauds revealed with the
chemiluminescence detection system of Roche Biochemicais (Lavai, QC) with
their protocols. In some cases, Western biots were reprobed with monoclonal anti
beta actin antibody (Clone AC-15, 1: 10000 dilution, Sigma-Aidrich, Oakville
ON).
Transfections and tucferase assays-Vaiidated Stealth DuoPak Smad2
(#12937-09), Smad3 (#12937-10) and Smad4 (#1293$-126) siRNAs and medium
GC content negative control siRNA (#12935-300) were transfected by calcium
phosphate precipitation method for adherent celis in suspension as described before
(41). Briefly, chondrocytes were released by trypsinization and 2.5 X celi
suspension aliquots incubated with 70 u1 siRNA (200-25 0 nM)-calcium phosphate
precipitate for 25 min with gentie agitation every 5 mm, 1 ml of 10% FCS-DMEM
added and plated in serum-containing medium for 3-4 h at 37°C for adherence.
Medium was removed, ceils washed with PBS, allowed them to recover for 24 h,
maintained in serum-free medium for 24 h and then stimulated with TGF-t3 for 24
h. Due to absence of matrix during transfection in suspended chondrocytes, this
method resuits in 80% transfection efficiency as determined with a fluorescent
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double-stranded RNA oligonucleotide. In other experiments, 2 t.ig of TIMP-3
promoter luciferase (-940 to +376 region) (42), cytomegalovirus (CMV)-driven
Renilla luciferase (0.2 p,g, transfection control) and rerspective siRNA (200 nM)
were cotransfected by the modified calcium phosphate procedure and afier
recovery, stimulated with TGf-3 and luciferase activity measured with Promega
Dual-Luciferase Reporter assay System (Promega, Madison WI) and Tumer
Designs Luminometer TD-20120 as recommended.
Construction of promoter deletions and analysis-The original TIMP-3
promoter plasmid obtained from Dr Jean Bennet (42) was a Sac I-Sac I fragment
from —940 to +376 regions. To generate shorter 5’ fragments, the sequence was
entered in the http://rebase.neb.com (New England Biolabs) database to find
unique restriction sites. Three unique sites including Asc I (at position —167), MSc
I (at position —333) and Kpn I (at position —828) were found and confirmed by
double restriction enzyme digestion (each of the three enzymes and Hind III site in
the polylinker region of pGL-3 basic vector) and 1.5% agarose gel analysis. The
Asc 1-Hind III (-167 to +376), MSc 1-Hind III (-333 to +376) and Kpn 1-Hind III (-
82$ to +376) were eluted and cloned into polylinker sites ofpGL3-Basic. Cloning
of the three fragments was confirmed by rapid plasmid extraction and double
digestion with Kpn 1-Hind III analysis of numerous clones, along with ffie original
TIMP-3 promoter plasmid with the Hind III and respective enzymes. These
constructs were purified by Qiagen QlAfilter Plasmid Midi Kit (Qiagen Inc.
Canada, Mississauga ON) and transfected as described above.
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Chromatin Immunoprecpitation (ChIP) analysis-Control and TGF-3
stimulated chondrocytes were fixed with 1% formaldehyde treatment, cross-iinked
chromatin prepared with ChP-IT and sheared with enzymatic shearing kit (Active
Motif Cat#53006 and 53007) and DNA-protein complexes immunoprecipitated
with negative control IgG or with Smad2, Smad3, Smad4 and SPi antibodies.
After proteinase K digestion, extraction and purification of DNA, TIMP-3
promoter fragments were amplifled by PCR with the TIMP-3 promoter-specific
primers from the —167, -333 and —940 and +1 regions and fragments detected by
2% agarose gel analysis.
Ail the experiments were performed at ieast 3 times and the resuits were
reproducible.
RESULTS
Role of $mad2 phosphoiylation in TGF-f3-stimulated TIMP-3 induction in
human chondrocytes-We previously showed that Smad2 is phosphorylated in
response to TGF-31 treatment (39). As reconfirmed in Fig 1, this observation is
highiy reproducibie. b investigate the possible invoivement of Smad2 in TGF-
induced TJMP-3 gene expression, chondrocytes were pretreated with previously
known inhibitors of Smad2/3 phosphorylation (43), PD169316 and $3203580 as
weli as their inactive analogue, $3202474 for 1 h and then stimulated with TGF-3
for 20 min. As shown in Fig lA, TGF-f3-stimulated Smad2 phosphorylation was
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inhibited by the 10-jtM dose of PD169316 and $B203580 but flot by SB202474.
The levels of total smad2 remained relatively constant (Fig 1 A, lower panel). Thus,
the role of Smad2/3 phosphorylation could 5e tested with these pharmacological
inhibitors.
To fiirther investigate the role of Smad2/3 in TIIvIP-3 gene regulation,
chondrocytes were pretreated for 60 min with the above-tested pharmacological
inhibitors and then stimulated with TGF-j3 for 24 h. Analogous to the resuits of
Smad2, TGF-f3-induced T1MP-3 protein expression could be inhibited by the
Smad2/3 phosphorylation inhibitors, PD169316 and SB203580 but flot by its
inactive homologue, SB202474. The levels of constitutively expressed fl-actin
levels remained unaffected (Fig lB). As these inhibitors are also known to block
p38 phosphorylation, role of Smad2 was further explored by the more specific
genetic approach of RNA interference (RNAi).
Blockade of TGF-t3-stimutated TIMP-3 increase by $mad2 siRNA-mediated
knockdown-We recently modified the classical Calcium phosphate transfection
procedure to conduct highly efficient transfections in chondrocytes by first
releasing them from their matrix and then transfecting with nucleic acids in ceil
suspension followed by their re-adherence in monolayers (41). Transfection of
Smad2-specific siRNA resulted in Smad2 knockdown while negative control
siRNA did not block Smad2 expression. Smad2-deficient chondrocytes displayed
severe down-regulation of TIIvIP-3 induction. Non-specific siRNA did not affect
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TIIvIP-3 induction thus demonstrating specific effects of Smad2 siRNA. The levels
of t3-actin were flot affected by any of the treatments (Fig 2).
Suppression of TGF-3-induced TIMP-3 expression by specfic inhibitor of
Smad3 ($153)-We investigated the foie of the other stimuiatory Smad, Smad3, in
TIMP-3 induction. Jinnin et al have recently described the specific inhibitor of
Smad3 (SIS3), which selectively abrogates Smad3 phosphorylation without
affecting Smad2 activation (44). Pretreatment with $1S3 dose-dependently
inhibited TGF-13-induced Smad3 phosphoryiation (Fig3A) and TIMP-3 protein (Fig
3B) expression without affecting the constitutive Smad3 or 3-actin levels.
Abrogation of TGF--induced TIMF-3 expression by Smad3 siRNA-To
further vaiidate the role of Smad3 in TTMP-3 induction by the recentiy introduced
genetic tool of RNA interference, chondrocytes were transfected with Smad3
siRNA or its negative control and then induced with TGF-f3. Smad3 siRNA but not
its negative controi siRNA drasticaiiy inhibited Smad3 phosphorylation and total
Smad3 expression (Fig 4A). Induction of TTMP-3 was simiiarly abolished by
Smad3 siRNA but not by the negative control siRNA (Fig 4B). The levels of 3-
actin in these extracts remained constant.
Inhibition of human TIMP-3 promoter activity by Smad2 and Smad3
siRNAs-To gain further insight into the mechanism of Smad-mediated TUVIP-3
regulation, we cotransfected chondrocytes with Smad2 or Smad3 siRNA along
with the human TIMP-3 promoter (-940 to +376)-iuciferase construct (42)
followed by induction with TGF-i3. As reported previously, TGF-f3 induces TIMP-3
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promoter-driven luciferase-activity (40). Negative control siRNA had very littie
effect whule Smad2 and Smad3 siRNAs significantly inhibited promoter activity
(Fig 5). These resuits with exogenous TflVIP-3 promoter mimic the endogenous
pattem of TIMP-3 protein expression.
Inhibition of TGF-f3-stimulated TIMP-3 enhancement by Smad4 siRNA
Since stimulatory Smad2 and Smad3 interact with co-Smad4 for TGF-$ signal
transduction, we investigated the role of Smad4 in TIMP-3 induction. Transfection
of Smad4 siRNA resulted in abrogation of the corresponding protein expression
that was flot affected by the negative control siRNA. Smad4-specific siRNA and
not its negative confrol siRNA diminished TGF-3-induced TLMP-3 protein
expression in human lmee chondrocytes without affecting the constitutive t3-actin
levels (Fig 6).
Identfication of minimal TGF-3 responsive TIMP-3 promoter-Considering
the responsiveness of the larger (-940 to +376) human TIIvIP-3 promoter to TGF-3,
we investigated the identity of minimal region responsible for TEv1P-3 induction by
this growth factor. Using the convenient restriction enzyme sites, we constructed a
series of TIMP-3 promoter deletion mutants. They span —$28 to +376 (named A—
828), —333 to +376 (named A—333) and —167 to +376 (called A—167) regions (Fig
7A). Functional significance of these promoter mutants was tested by transient
transfections and analysis of luciferase activity, which revealed that —828 deletion
retained the original promoter activity while —333 and —167 deletions displayed
somewhat reduced activity. Thus, most of the TGF--responsive region is localized
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within the -333 region and additional cis-acting elements may be present in the
upstream regions (Fig 7B).
Confirmation of Smad interaction with the TIMP-3 promoter by ChIP
analysis-To investigate whether Smads indeed bind with the TIIVIP-3 promoter
region in vivo, chromatin from untreated and TGF-13-treated chondrocytes was
immunoprecipitated with different Smad antibodies. Analysis of DNA in the DNA
protein compiex with specific primers (-940 to +1, -333 to +1 and —176 to +1)
revealed that Smad2 and Smad4 antibodies were able to immunoprecipitate —940
and —333 TIMP-3 promoter fragments, thus confirming binding. The expected
Smad3 binding could not be demonstrated possibly due to lack of ChW-quality
antibody (Fig. 8). The —167 fragment which contains Spi binding sites
immunoprecipitated with the Spi antibody.
DISCUSSION
TGF-3 is an important growth factor for cartilage development
(chondrogenesis), its maintenance and regeneration. Similarly, TIMP-3 is a major
natural inhibitor of MMPs, aggrecanases and lACE, the enzymes implicated in
cartilage degradation and joint inflammation. By several phannacological and
genetic approaches, we have demonstrated for the first time that Smad pathway is a
pivotai mediator of TIMP-3 regulation by TGF-t3 and TIIvfP-3 gene is a Smad
pathway target. We have further shown that the regulation is primarily at the
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promoter level and most of the TGf-i3 responsive elements could be found within
the —333 to +1 region ofthe promoter where Smads bind in vivo.
liffiibition of TIMP-3 induction by phannacological inhibition of Smad2
and Smad3 phosphorylation strongly suggested the implication of Smad pathway in
TIMP-3 regulation. This inhibition was specific, as the equivalent amount of an
inactive inhibitor did flot suppress Smad2 phosphorylation and TIMP-3 induction.
These resuits were reinforced by the alternative and more powerful genetic
approach of Smad2 and $mad3 siRNA-mediated knockdown. Similar induction of
endogenous TIMP-3 and exogenous TIMP-3 promoter-luciferase activity by TGF
t and their inhibition by Smad2 and Smad3 siRNA suggests that TTMP-3 promoter
is responsive to these agents and regulation most probably occurs at the level of
promoter as Smad2 and possibly Smad3 bind with the TIMP-3 promoter
sequences. Lack of Smad3 binding in ChIP anlaysis may be possibly due to quality
of the available Smad3 antibody which is good enough for Western blotting but flot
for the ChIP analysis. Thus both receptor-activated stimulatory Smad2 and Smad3
may be required for TGF-3-induction of TIMP-3. This is in contrast with Smad2
and Smad3 knockout murine embryonic fibroblasts where selective requirement of
Smad2 for MMP-2 and that of Smad3 for c-fos, Smad7 and TGF-3 was observed
(45).
Smad2 phosphorylation is reduced during the progression of murine OA
(46). Smad2 deficiency delays TGF-3-mediated Meckel’s cartilage development
showing its strong association with different types of cartilage (47). In this respect,
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it is interesting to note that Smad3 knockout mice display enhanced chondrocyte
maturation and develop osteoarthritis-like degenerative syrnptoms, suggesting that
Smad3 is required for the maintenance of articular cartilage (38,48). Smad3
overexpression in mesenchymal stem celis leads to primary chondrogenesis (49).
TGF-3 binding of an ECM protein, asporin, with aspartic acid repeats
polymorphism leads to greater inhibition of TGF-3 signaling and increased
susceptibility of certain Japanese patients to hip and knee OA (50). Diminished
TGF-/3 receptor in older mice may be one of the causes of OA development (51).
Thus Yack or alteration in TGF-i3 signaling and its target genes could severely
impair the cartilage homeostasis. Indeed, TEvIP-3 knockout mice display increased
collagen and aggrecan degradation with aging in a manner similar to osteoarthritic
patients (30). In a gene array study, TIMP-l was found to be a target of Smad3 in
human dermal fibroblasts (52). In contrast, TIIvIP-l is stili induced by TGF-3 in
Smad knockout celis (53). Smads were also shown to bind with the rat TIIvIP-l
promoter (54). Smad signaling is also required for TGF-t3 induction ofMMP-l and
MMP-13 in chondrocytes, squamous carcinoma ceils and dermal fibroblasts (55-
57).
Smad4 interaction with Smad2/3 is required for TGF-3 signal transmission
(58). Constitutive Smad4 protein expression is in agreement with a previous study
where Smad4 mRNA expression was shown in both normal and OA chondrocytes
without any major differences (59). Coordinate inhibition of TIIvIP-3 in Smad4-
depleted celis strongly support the requirement of Smad4 for induction of TIMP-3
77
by TGF-f3 in articular chondrocytes. This is in contrast with the well-known TGF-f3
responsive plasminogen activator inhibitor (PAT) gene, which is induced in the
absence of Smad4 (60), though both Smad3 and Smad4 bind with the promoter of
the PAl gene (61). Smad4 knockout animais are dwarf and have disorganized
growth plate suggesting its requirement for hypertrophic chondrocyte
differentiation and proper growth plate organization (62). Smad7 overexpression
downregulated chondrocyte proliferation, PAT gene induction and proteoglycan
synthesis (63). Smad7 overexpression can also block synovial fibrosis while
maintaining TGF-3-dependent cartilage repair (64). However, its partial inhibition
by siRNA had no effect in our system (resuits not shown).
The TGF-3 responsive elements in human TIMP-3 promoter have not been
defined. Spi sites in tins fragment are important for its regulation by ERK and Md
pathways (40, 41). By constructing serial 5’ deletions of the larger TUVW-3
promoter fragment and by conducting transfections of the deletion mutants, we
were able to define minimal 333 bp TGf-(3-responsive region. Additional upstream
sequences may also be important for full responsiveness to TGF-3. This region
contains Spi and some partial $mad binding elements (SBEs). The —167 fragment
binds with Spi only and flot with Smads. One possibility is that Smad2/3/4
complex bind directly with SBEs in the TUVIP-3 promoter region. ChIP analysis
supported this view. Altematively, Smads may interact with Spi to activate TIMP
3 promoter. Smad3-$pl interaction occurs in the TGF-t3-induced tenascin-C
promoter (65). $mad3 -Spi interaction is needed for full erythropoietin promoter
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activity (66) and the well-characterized, TGF-t9-induced PAl (67) and collagen (68)
promoters.
We have previously shown the requirement of Erk and Alct pathways for
TGf-L3 induction of TIIvIP-3. Induction of multiple pathways by TGF-/3 in
association with TIMP-3 has also been observed in other systems. Both Smad and
p38 pathways are known to independently and additively regulate excessive
deposition of collagen I in hepatic stellate celis during liver fibrosis (69). In TGF-t3
induction of biglycan in pancreatic celis, p38 was activated downstream of Smad
pathway (70). Aggrecan induction by TGF-3 in chondrocytic celis occurs by cross
tallc of Smad, ERK and p38 pathways (71). Both ERK and Smad2 are activated
during TGF-f3-induced chondrogenesis (72). Thus multiple pathways and their
interactions may activate the human TllvfP-3 gene.
In summary, we have shown by pharmacological inhibition and RNA
interference-mediated knockdown approaches that TGF-t3 receptor-activated
Smad2 and $mad3 and co-$mad4 are required for induction of TIMP-3 expression
and promoter activity by TGF-3. We have also identified a minimal TIMP-3
promoter fragment needed for this TGF-$ response where Smad2 and Smad4 bind
in vivo. Thus TIMP-3 gene is a target of the $mad pathway. These mechanisms of
TllvfP-3 regulation may be pivotai in TGF-13-stimulated cartilage ECM synthesis,
repair and maintenance.
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Figure Legends
Figure 1. PD169316 and SB2035$0 but flot the inactive analogue, SB202474
inhibit TGF-f3-induced Smad2 phosphorylation and TIMP-3 protein expression
without affecting constitutive beta-actin levels in human articular chondrocytes.
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Quiescent confluent chondrocytes were either treated with vehicle (DMSO and
PBS with 0.1% BSA and 4 mM HCI) as control or pretreated with 5 or 10 iM of
PD169316, SB203580 and SB202474 alone for 60 min and then stimulated with
TGF-3 for 20 min (Smad2) or 24 h (TIMP-3). A) Upper two panels are phospho
(p-Smad2) and total Smad2 Western blots while B) lower two panels represent
TIMP-3 and beta-actin Western blots. The lower graphs shows densitometric
normalized value of pSmad-2 and TIMP-3 proteins in percentage. Data are
presented as the mean ± SEM of three independent experiments. P< 0.05 was
considered significant.
Figure 2. Smad2-specific siRNA and not its negative control siRNA suppresses
Smad2 expression and TGFfl-induced TIIVEP-3 protein expression in human knee
chondrocytes without affecting constitutive beta-actin levels. Articular
chondrocytes were either treated with vehicles (Control) or transfected with 200
nM ofnegative control or Smad2 small interfering RNA (siRNA) and then exposed
to TGF-3 for 24 h. The panels represent Smad2 (upper), TIMP-3 and beta actin
(lower) western blots. The lower graph shows densitometric normalized value of
Smad-2 and TIMP-3 proteins in percentage. Data are presented as the mean ± SEM
ofthree independent experiments. P< 0.05 was considered significant.
Figure 3. Specific inhibitor of Smad3 (SIS3) dose-dependently inhibits TGF-t3-
induced Smad3 activation and TIIVIP-3 protein expression in human knee
chondrocytes. Quiescent chondrocytes were either treated with vehicle (control) or
pretreated with 5 or 10 1iM of S1S3 alone for 60 min and then stimulated with
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TGF-3 for 20 min (A) or 24 h (B). In A) upper and lower panels represent
phosphorylated and total Smad3 levels respectively. In B, TIMP-3 and beta-actin
Western blots are shown. Dose-dependent Smad3 phosphorylation and TIMP-3
inhibition by SIS3 without affecting constitutive beta actin can be noticed. Graphs
A shows densitometric normalized value of pSmad-3 in percentage where as graph
B shows TIMP-3 proteins. Data are presented as the mean ± SEM of three
independent experiments. P< 0.05 was considered significant.
Figure 4. Smad3-specific siRNA and flot its negative control siRNA suppresses
TGF-f3-induced Smad3 phosphorylation, Smad3 and TIMP-3 protein expression in
human knee chondrocytes. Articular chondrocytes were either treated with vehicles
(Control) or transfected with 200 nM of negative control or Smad3 small
interfering RNA (siRNA) and ffien exposed to TGF-3 for 24 h. In A) specific
inhibition of phosphorylated (p Smad3) and total Smad3 is shown wiffiout any
affect on beta actin level. hi B), besides $mad3 (upper panel) and TIMP-3 (middle
panel) suppression by Smad3 siRNA, the unaffected beta actin (lower panel)
Western blots are depicted. Graphs A shows densitometric normalized value of
pSmad-3 and total Smad-3 in percentage where as graph B shows Smad-3 and
TIIVIP-3 proteins. Data are presented as the mean ± SEM of three independent
experiments. P< 0.05 was considered significant.
Figure 5. Smad2- and Smad3-specific siRNAs down-regulate TGF-3-induced
TIMP-3 promoter-luciferase activity in human chondrocytes. Human knee
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chondrocytes were transiently cotransfected with the 2 ig of human flMP-3
promoter-firefly luciferase vector, 0.2 pg of a plasmid expressing Renilla luciferase
(internai control) and 200 nM Smad2 or Smad3 siRNA as indicated. Ceils were
then treated with TGF-3 for 24 h. Extracts were analyzed for luciferase activity.
The values of firefly luciferase to Renilla luciferase ratios were plofted with Prism
3.0 software. Data are presented as the mean ± SEM of three independent
experiments. P< 0.05 was considered significant.
Figure 6. Smad4-specific siRNA diminishes Smad4 expression and TGF-3-induced
TEvIP-3 protein expression in human chondrocytes. Articular chondrocytes were
either treated with vehicles (Control) or transfected with 200 nM of negative
control or Smad4 small interfering RNA (siRNA) and then exposed to TGf-/3 for
24 h. Specific inhibition of Smad4 (upper panel) and TIIvIP-3 (middle panel) and
unaffected expression of beta actin (lower panel) by Western immunoblotting are
depicted. Graphs shows densitometric normalized value of Smad-4 and TIMP-3
proteins in percentage. Data are presented as the mean ± SEM of three independent
experiments. P< 0.05 was considered significant.
Figure 7. Design ofTllVIP-3 promoter deletion mutants and their impact on TGF-3-
induced luciferase activity in human knee chondrocytes. A) The starting TIIvIP-3
promoter fragment is shown in the top panel. By using Kpn I, MSc I and Asc I in
combination with Hind ifi sites (inverted arrows), TIMP-3 promoter segments
were cloned in pGL-3 basic upstream of luciferase (LUC) gene. +1 and long arrow
indicates transcription start site. z, deletion. B) Human chondrocytes were
90
transiently cotransfected with the 2 jig of original or deleted human TIMP-3
promoter-firefty luciferase vector and 0.2 ig of a piasmid expressing Renilla
luciferase (internai control) as indicated. Celis were then treated with TGF-3 for 24
h. Extracts were analyzed for luciferase activity. The values of firefly luciferase to
Renilia luciferase ratios were plofted wiffi Prism 3.0 software. Data are presented
as the mean ± SEM of three independent experiments. P< 0.05 was considered
significant.
Figure 8. Binding of Smads and Spi with the human TTMP-3 promoter by
Chromatin immunoprecipitation (ChIP). Human articular chondrocytes were either
treated with vehicle (-) or with TGF-/3 (+) for 60 mm, fixed with formaidehyde,
sheared enzymaticaiiy and precipitated with the control (IgG) and indicated test
antibodies. Foliowing purification of DNA, genomic promoter fragments were
ampiified by PCR with the primers from the indicated (lefi of the figure) regions
and products analyzed by agarose gel. Input DNA is an aliquot of DNA purified
prior to immunoprecpitation.
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GENERAL DISCUSSION
Extracellular matrix is degraded by MMPs, which are inhibited by TIMPs. There
are four types of TllvEPs. TTMP-1, TIIvIP-2 and TIIvIP-4 are secreted in soluble
form, where as TIMP-3 is associated with ECM and is an important protein for
cartilage maintenance and repair in arthritis. TGF-3 has an important role in ceil
proliferation, differentiation and apoptosis in different types ofcells (197).
In the first part of this study (article 1), we have shown for the first time
involvement of ERKIMAPK pathway and that transcription factor Spi is required
for TGF-j3-induced TTMP-3 expression in bovine chondrocytes and human
SW1 353 chondrosarcoma ceils. TGF-f3-stimulated phosphorylation of ERKs in
both bovine and human chondrocytes (article 1, Fig 1) suggests the involvement of
this pathway in two different species. The activated ERKs have been implicated in
many studies associated with chondrocytes survival. TGF-3 reduced the
lipopolysaccharide (LPS)-induced catabolic effects and increased pERK2 levels in
human articular chondrocytes (198). Dexamethasone (DEX) suppressed TGF-f3-
induced proliferation of cultured rat articular chondrocytes (CRAC) and collagen
II by inhibiting ERK and AP- 1, which suggests the involvement of ERK pathway
in CRAC growth (199). ERK pathway is also involved in aggrecan induction by
TGF-3 in chondrogenic, ATDC5 cells (200). The ERK activation by IGF- 1 plays
important role in maintaimng chondrocytic phenotype (201). As the ERK-MAPK
pathway is associated with increased proliferation and maintenance of
chondrocytes, prolonged activation of this pathway observed in this study, could
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have profound impact on these processes and TGF-3 target genes, such as TIMP-3.
Apoptosis is one of the mechanisms of cartilage loss in OA (202) and stimulation
of the prosurvival ERK pathway by TGF-$ may have an antiapoptotic effect in
chondrocytes. Lei et aI (203) reported that TGF-t3 signaling enhance the survival of
breast carcinoma MCF celis through the activation ofERK (phosphorylated form).
Abrogation of TGf-3 signaling with dominant negative type II receptors (DNRII)
or treating with type I receptor inhibitor increased apoptosis in MCf celis.
Downregulation of TGF-3-induced pERK, TIIvIP-3 protein and RNA by
phannacological inhibitors, PD9$059 and U0126, (Article 1, fig. 2, 3,4) suggest
that ERK-MAPK is partly involved in TGF-j3-induced TllvIP-3 expression in
human chondrocytes, a process that is also conserved in bovine chondrocytes.
Kwak et al reported similar results for TGF-t3-induced TIMP-i in human
fibrosarcoma celis (HT1O8O). Treatment of ceils with TGF-13 stimulated the
phosphorylation of ail three mitogen-activated protein kinases (ERK1 /2, p3 8, JNK)
and AKT, but the inhibition of only ERK1/2 pathway by PD98059 and
transfection of dominant negative MEK1 inhibited the TIMP-1 induction by TGF
i suggesting the major role ofERK1/2 pathway (204).
Spi is an important transcription factor, which is involved in the inducible
expression of a number of genes. Spi is the member of Sp family of proteins,
which are structurally closely related to each other. Structurally, Spi protein
consists of several domains, N-terminal inhibitory domain, serine/threonine
(Ser/Thr)-rich domain, glutamine-rich domain and C-terminal zinc finger DNA
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binding domain (ZFDBD). The ZFD3D is highly conserved region among the Sp
family proteins and play important role in binding to DNA. The phosphorylation
of Ser/Thr is important for the regulation of Spi activity (205). TGF-3 stimulates
serine phosphorylation of Spi in fibroblasts from Scieroderma patients (206).
Phosphorylation of Spi at threonine 453 and 739 enhances binding of Spi with its
target sequence (207). Spi binds to the GC boxes in the promoter regions (205)
and human T1MP-3 promoter contains at least 4 Spi consensus sites between -112
to +15 flanldng region (196). Jnhibition of endogenous TIIvIP-3 RNA and protein
induction by the pharmacological agents, mithramycin and WP63 1, (article 1, fig.
5, 6) suggest that this transcription factor is required for TGF-13-induced TIIVIP-3
expression in chondrocytes. Electrophoretic mobility shift assay (EMSA) showed
that TGF-3 enhanced the Spi DNA binding activity while mithramycin
dowiwegulated this binding (article 1, Fig. 7). These resuits were reinforced by the
alternative genetic approach. Transfection of Spi transcription factor antisense
ODN completely knocked down the Spi protein leading to inhibition of TIMP-3
protein expression (article 1, Fig, 9), where as the overexpression of Spi enhanced
TIMP-3 promoter activity (article i, Fig. 8). The involvment ofERKi/2 followed
by Spi transcription factor is also reported in TGF-fl stimulated TIIVIP-1
expression in HT1O$O ceil for anti-invasive and anti-migration activities (204).
BMP2 induced osteoblast differentiation in mesenchymal ceils (C3H1OT1/2)
through up-regulation of ERK and Spi mediated transcription mechanism (20$).
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Dur results with TIMP-3 gene support the concept that Spi is an important link
between increased activation ofERK pathway and its target genes (207).
The ERK pathway is a linear cascade ofprotein kinases, including Ras, Raf’ MEK
and ERK. ERK pathway is activated by growth factors and is constitutively
activated in many celi unes. During the activation of ERK pathway Raf is recmited
to the membrane and binds to Ras-GTP. This recruitment of Raf to Ras-GTP is
necessary but not strong enough for the full activation of Raf (209). Previous
studies have shown that other factors feed into the ERK pathway at Raf and some
of the candidate molecules are Src, membèr of the protein kinase C (PKC) and
PI3K (210).
Dur resuits have shown that the inhibitor of ERK pathway, PD9$059, does flot
inhibit the TGf-3-induced activation of PI3K pathway (Article 2, Fig. 1 E),
whereas the inhibitors of PI3K pathway, LY294002, wortrnannin, and NL-71-101
inhibit the PI3K pathway. Based on these resuits, it appears that TGF-3-induced
PI3K signaling is independent of the ERK pathway.
The modulation of ERX pathway by PI3K cascade is controversial. In COS-7
celis, the expression of activated form of pliOy type of P13-kinase has been
reported to stimulate the ERK pathway, but pilOa could flot. The ERK activity
was abolished by wortmannin indicating that PI3K’y can mediate wortmannin
sensitive activation of ERK (211). Wortmannin also inhibits PDGF-induced
activation of Raf in CR0 ceils, indicating that PI3K is required for the activation
ofRaf in these ceils (212). Conversely in the human breast cancer ceil une MCF-7,
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the IGF-1-induced AKT directly phosphorylated Raf-1 on serine-259 and
decreased the Raf- 1 activity leading to proliferation. High Raf- 1 activity in MCF-7
ceils induced growth arrest by activating celi cycle inhibitor p2l’’” PI3K inhibitor
LY294002 inactivates the cross talk between the two pathways and switches the
biological response from proliferation to growth arrest (213).
li our study we have used TGF-f3, and secondly IGF-1 does not induced TUVIP-3
protein (data flot shown), so the downregulation of ERK pathway by PI3K
pathway cannot be expected. However, there may be some sort of interaction
between the two pathways.
In the second part of this study, we have investigated the involvment of PI3K
pathway in TGF-3-induced TIMP-3 expression in human chondrocytes. The
involvment of TGf-f3-induced PI3KIAKT pathway is well known for its
prosurvival role in many ce!! types i.e. TGF-3-induced PI3KJAKT dependent
differentiation of epithelial to mesenchymal ceils (214). PI3KJ AKT pathway is
also involved in BMP2-induced anti-apoptotic effect in chondrocytic celi une,
N1511 (215). Krymskaya et al demonstrated the co-immunoprecipitation of the
p85 subunit of PI3K along with both TGF-f3 receptor I and II, and showed that
TGF-fi receptor I can modulate the EGF-stimulated PI3K activity in the human
airways smooth muscle celis (hASM) (216).
We have shown here by several pharmacological and genetic approaches that
PI3K!AKT pathway mediates TGf-13-induced TIMP-3 gene expression through
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Spi transcription factor activity. We also found that TIMP-3 gene expression is
reguiated at the translation level via mammalian target of rapamycin. TGF-/3
induces phosphorylation ofPKB/AKT time-dependently in a delayed manner after
4 hours (article 2, Fig. 1 B, C, D) as compared to Smad2 and ERK phosphorylation
that is induced by TGF-3 rapidly within 20 min to 1 hour (2 17,218). This suggests
early events such as cross talk with other pathways or intermediate early factors.
Previous studies have reported a link between PI3K and p38 MAPK pathway.
TGF-3 induces rapid activation of p38 MAPK, which is followed by a delayed
activation (12 hours) of PI3KJAKT pathway. p38 MAPK-dependent production of
growth factors (possibly FGF-2 or IGF-1) that function in an autocrine manner
were responsible for the activation of PI3KJAXT pathway, which confer resistance
to apoptosis in human lung fibroblast celis (219). In our study we have tried to find
this intermediate growth factor and hypothesized that it may be insulin-like growth
factor (IGF-1) but our resuits showed that TGF-fl did not induce IGF-1 at any time
point between 20 min to 24 h. IGF-1 also did flot induced TIMP-3 expression at
various doses in human chondrocytes. Furthermore, blockade of IGF-1 receptor
did not affect induction of TEvIP-3 by TGF-3. Thus TGF-3 effects do flot seem to
be mediated by IGF-1 (resuits flot shown). TIMP-3 has been shown to induce
apoptosis in rheumatoid arthritis synovial fibroblast and in many different ceil
types (220,22 1). However our study suggests ffie pro-survival role of TGF-
inducd PI3KJAKT in chondrocytes. Indeed, TGF-f3 is a cartilage growth
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promoting factor and plays anabolic role in matrix synthesis, celi proliferation and
osteochondrogenesis (222).
The TGF-f3-induced PI3K survival pathway lias been demonstrated in many other
celi types. TGF-3 induces elastin mRNA tbrougli PI3KJAKT pathway in human
embryonic lung fibroblast that is inhibited by inhibitor LY294002 (223). TGF-fl
exerts its growth and antiapoptotic effects through the P13-kinase/AKT pathway in
human RA synovial and normal fibroblasts (224). Insulin induces chondrogenesis
of ATDC5 celis mainly by PI3K pathway (225). In chondrocytes, TGF-f
stimulated Smad2 and ERK phosphorylation is followed by AKT phosphorylation
and these pathways or their interactions are needed for TIMP-3 induction (this
work, 217,218). N-terminal human T]MP-3 inhibits the cleavage of
glycosaminoglycan release in bovine nasal and porcine articular cartilage explants,
treated with IL-la and very littie apoptosis was observed in porcine chondrocytes.
(226). Similarly, TE\4P-3 may also be anti-apoptotic, as knockout of this gene
results in increased apoptosis in mammary gland (63). This is fiirther supported by
another study where TIMP-3 promoted proliferation of non-transformed celis
under low-serum condition (227). TIMP-l lias also been shown to exert its anti
apoptotic effects through PI3KJAKT pathway in erythroid celis. Bad is a member
of Bd-2 family, which is pro-apoptotic. Bad phosphorylation by AKT leads to its
sequestration by 14-3-3 protein and inhibits its heterodimerization with Bcl-XL, a
pro-survival factor with anti-apoptotic activity (228). TIMP-3 role seems to be pro
apoptotic as well as anti-apoptotic and it might be possible that physiological
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levels of TIMP-3 promote survival and non-physiological levels induce apoptosis.
TGF-fl-induced AKT phosphorylation and TIIVJP-3 protein induction suggests a
direct relation between the two events, as demonstrated in our subsequent
experiments. Inhibition of TIMP-3 mRNA and protein by two different
pharmacological PI3K inhibitors Wortmannin, LY294002 and by siRNA for PI3K
(article 2, Fig. 2 A, B, C) strongly support the foie of PI3K in TEVIP-3 induction.
Similarly, suppression of TGF-f3-induced TIIvIP-3 mRNA and protein expression
by AKT/PKB inhibitor, Ni-71-101 and AKT siRNA (article 2, Fig. 3 A, B)
reinforces the involvement of AKT/PKB in TGF-3 signal transduction leading to
TIMP-3 induction. It is iikely that several growth factors utilize this pathway to
promote ECM synthesis, growth and survivaL
TIMP-3 promoter-reporter transfection studies suggest that the 5’ flanldng region
spanning —940 to +376 contains most of the TGF-t3 responsive sequences. This is
in agreement with a previous study where region from —463 to +1 was shown to be
responsible for serum-stimulated ceil cycle progression; serum contains a
heterogeneous mixture of growth factors (196). We have also demonstrated the
inhibition of TGF-j3-induced TIMP-3 promoter-driven luciferase activity by the
pharmacologic inhibitors, wortmannin, LY294002 and AKT siRNA (article 2,
Fig.4), which showed that this promoter region is the target of TGF-t3 stimulated
PI3KIAKT pathway. Human TJMP-3 promoter contains Spi binding sequences,
which are important mediators of TIMP-3 expression (218). The involvement of
Spi transcription factor was reconfirmed by the newly developed RNA
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interference-mediated Spi knockdown, which resulted in inhibition of TGF-t3-
induced TIMP-3 gene expression (article 2, Fig. 5A). Spi activity was measured
by a newly developed ELISA based assay. The inhibition of TGF-13-induced Spi
activity by the inhibitors Wortmannin Y294002, NL-71-l01, and siRNA for AKT
further support Spi (article 2, Fig. 5B) as a possible target of AKT pathway. Spi is
a pivotai factor for the expression of various genes related to ECM synthesis, celi
cycle and growth (i41,229). Spi has an important role in the induction of TIIvIP-l
as demonstrated by mutation analysis and cotransfection of anti-sense
oligonucleotide (230). In other systems, increased expression of vascular
endothelial growth factor by AKT required Spi as demonstrated by Spi siRNA
driven kriockdown (231). Through the phosphorylation of various substrate, the
activated AKT/PKB regulates various biological processes such as celi survival,
celi cycle, growth, glucose metabolism and transcription factors that regulate gene
expression.
The inhibition of PI3K pathway with wortTnannin, LY294002, PI3K siRNA, AKT
inhibitor, NL71-ioi, and AKT siRNA (Article 2, Fig. 2A, B, C, 3A, B) ail have
shown decreased expression of TIMP-3 protein indicating the blockade of PI3K
pathway. This effect clearly seems to be due to the downregulation of mTOR, a
downstream effector of AKI. The inactive AKT cannot activate mTOR, which
regulates the protein transiational machinery through the phosphorylation and
activation of p70S6 kinase. The inhibition of mTOR by rapamycin (Article 2, Fig.
6A) decreased the expression of p70S6 kinase and TJMP-3 protein. This
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mechanism appeared to be specific, as the levels of 13-actin were flot affected. The
inhibition of TIIvIP-3 protein expression by rapamycin seems to be due to decrease
in its translation as this drug did flot affect TIIvIP-3 mRNA induction levels. The
inactivation of p70S6 kinase simultaneously resuits in the activation of eukaryotic
initiation factor 4E binding protein 1 (4E-BP1), which inhibits the initiation of
translation (232,233). The synthesis of the signaling intermediates of ERK and
Smad pathways might 5e under the control of this transiafional machinery and
their expression decreases on inhibition of PI3K pathway leading to complete
inhibition of TIIvIP-3 protein expression. The same type of transiational control
was also observed in IGf-I stimulated synthesis of proteoglycan in chondrocytes,
which requires involvement of the PI 3-kinase pathway and was inhibited by
rapamycin (234).
hi the third part of this study, by using pharmacological and genetic approaches,
we have investigated the involvement of Smad pathway in TGF-t3-induced TIIVIP-3
induction in human chondrocytes. The deletion mutant analysis of TIIvIP-3
promoter has further revealed that the region between —167 to +376 contains
sequences which are responsive for the minimal expression of TGF-3-induced
TIMP-3 expression where as the upstream region is also responsible for enhanced
expression in chondrocytes.
Inhibition of TLMP-3 induction and $mad2 phosphorylation by pharmacological
inhibitors, PD169316 and SB203 580 strongly suggested the involvement of Smad
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pathway in TIMP-3 regulation whereas the equivalent amount of an inactive
inhibitor SB202474 did flot suppress Smad2 phosphorylation and TIIVIP-3
induction (article 3, fig. 1). The involvement of Smad is further confirmed by
using a Smad3 inhibitor, SIS3, which decreases the TGF-f3-induced TIIvIP-3
expression (article 3, Fig. 3). These resuits were reinforced by the alternative and
more powerfiil genetic approach. The transfection of siRNA for Smad2, Smad3
and Smad4 completely knockdown (article 3, Fig. 2, 4, 6) the respective genes and
T]MP-3 expression, indicating a direct correlation between Smad proteins and
TIMP-3 gene expression. A slight increase irt the total Smad2/3 expression (article
3, Fig. 2, 4) on treatment with TGF-f and control siRNA might be due to induction
of these proteins by TGF-t3 and control siRNA. Similar induction of TIIVIP-3
promoter-luciferase activity by TGF-3 and their inhibition by Smad2 and Smad3
siRNA suggests that TIMP-3 promoter is responsive to these agents and regulation
most probably occurs at the level of promoter (article 3, Fig. 5) Thus both
receptor-activated stimulatory Smad2 and Smad3 are required for TGF-13-induction
of TIMP-3.
The siguificance of Smad proteins association with chondrocytes survival has been
reported in many studies. Inimunohistochemical studies in murine OA model have
shown that the loss of proteoglycan was associated with reduced level of TGF-3
and Smad2 phosphorylation. Severely damaged articular cartilage was completely
negative for pSmad2. The reduced TGF-f3 and pSmad2 expression in damaged
cartilage suggest the involvement of Smad pathway and protective role of TGF-13
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in cartilage. TGF-$ and pSmad2 are upregulated in chondrogenesis (235). In the
perichondrium, Smads-mediated TGf-3 signaling is well documented in the
development of long bones. The infection of organ culture with adenoviral vector
containing dominant negative mutant of $mad2 and Smad3 showed that $mad3 is
partially required for the proper hypertrophic differentiation of chondrocytes, as
the $mad2 can compensate for the loss of Smad3. However, Smad3 is required for
regulating chondrocyte proliferation (236). Smad2 mutant mice showed
abnormalities in craniofacial development (237) where as Smad3 kuockout mice
displayed enhanced chondrocyte maturation, developed osteoarthritis, skeletal
abnormalities and died within 10 months (79,238,239).
The knockdown of Smad3 decreased proteoglycan synthesis and COL2A1
expression while double kockdown of Smad2/3 resulted in strong inhibition of
chondrogeneic differentiation in human mesenchymal cells (240). In fibroblast,
COL1A2, COL3A1, COL6A1, COL6A3 and tissue inhibitor ofmetalloproteases-l
are Smad3-mediated TGF-3 target genes (241). Smad3 maintained articular
cartilage by inhibiting chondrocyte hypertrophic differentiation and targeted
disruption of Smad3 resulted in degenerative joint disease resembling human
osteoarthritis (79). A single base mutation from A to T resulting in the change of
amino acid asparagines to isoleucine in the Smad3 protein was found in an
osteoarthritic patient indicating that TGF-f3/Smad3 signaling disturbance is
involved in human osteoarthritis (242).
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Our study further showed that knockdown of Smad4 resulted in inhibition of TGF
t3-induced TIMP-3 expression (Article 3, Fig. 6) in chondrocytes suggesting the
involvement of Smad4 in signal transduction. This is in contrast with plasminogen
activator inhibitor (PAl) gene, which is induced in the absence of Smad4 (243),
though both Smad3 and Smad4 bind with the promoter of the PAT gene (244).
Smad4 knockout animais are dwarf and have disorganized growth plate suggesting
ils role in hypertrophic chondrocyte differentiation and requirement for proper
growth plate organization (245). Smad7 is an inhibitory Smad and transiocates
from nucleus to cytoplasm on TGF-f3 stimulation, which then competes for binding
to the activated type I receptor and inhibits Smad2I3 phosphorylation (246). Our
experiments, showed that knockdown of Smad7 by Smad7 siRNA decreased the
expression of Smad7 (data flot shown). Normally, low Smad7 level could have
lead to decreased inhibitory action. This decreased inhibitory action however,
could not increase TIIvIP-3 expression, which might be due to an already stronger
TGF-$ interaction with TGF-3 receptors and Smad2/3.
The TGF-t3 responsive elements in human TIMP-3 promoter have not been
defined. Spi sites in tins fragment are important for its regulation by ERK and
AKT pathways (218,247). In order to see the degree of responsiveness by various
regions of human TflvIP-3 promoter, we have made serial 5’deletions of the larger
TIMP-3 promoter. Transfection studies of these mutants have revealed the
requirement of minimal fragment A—167 for TGF-f3-induced flMP-3 promoter
iuciferase activity (article 3, Fig. 7B) Additional upstream sequences may also 5e
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important for full responsiveness to TGF-t. Gene3 software analysis lias shown
that this fragment contains 4 Spi binding sites. The sequences analysis has also
shown that upstream fragment in TIMP-3 promoter contains number of Smad
binding elements (SBEs) as shown in Fig. E. Our study clearly shows that these
SBEs are co-operatively enhancing TIIvIP-3 promoter luciferase activity.
Chromatin immunoprecipitation analysis revealed that Smad2, Smad4 and Spi
antibodies were able to immunoprecipitate —940, -333 and —167 TIMP-3 promoter
fragments (article 3, Fig. 8) showing the in vivo binding of these proteins with
DNA. The expected Smad3 binding was nbt observed, which may be due to the
Iack of ability of Smad3 antibody to bind with Smad3 in contact with DNA.
One possibility is that Smad2/3/4 complex bind directly with SBEs in the TIMP-3
promoter region. Another possibility is that Smads may interact with Spi directly
or may be through some third partner to activate TEVIP-3 promoter. Smad-Spl
interaction has been reported in many studies. Smad3-Spi interaction was
observed for COL1A2 promoter in the TGF-3-induced normal fibroblasts (248).
Smad3-Spi interaction is needed for full erythropoietin promoter activity (249).
Smad2, Smad3 and Smad4 complex interact with Spi in the induction of cyclin
dependent kinase inhibitor [p15(hik4B)] gene by TGF-3 in epithelial celis (250).
A physical interaction between AKT serine tbreonine kinase and Smad3 modulates
the Smad pathway by PI3K pathway stimulated by IGF- 1 in hepatocytes. The
AKT inhibits Smad3 activation by inhibiting its phosphorylation, complex
formation with Smad4 and nuclear transiocation. The AKT inhibits the
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phosphorylation of Smad3 by inducing the membrane localization of AKT, which
directly binds to Smad3 and prevent Smad3 availability to TGF-t3 receptor I. TGF
3 induced pSmad3 does flot bind with AKT. High levels of pSmad3 induce
apoptosis in hepatocytes, whereas AKT antagonizes ifiis effect and promotes
survival (251, 197). In our study the PI3K pathway is activated in a delayed
mamer by TGF-3, which might have played some anti-apoptotic role and
promoted T1MP-3 induction, which has a pro-survival role. Although TIMP-3 has
been implicated in apoptosis in other celi types, we have flot observed any
apoptosis in chondrocytes by TGF-/3 induction ofTIMP-3.
Conversely, another study has shown that PI3K pathway modulates positively
Smad3 transcriptional activity. The COL 1A2 expression by TGF-3-stimulated
Smad3 was partially blocked by LY294002 and AKT dominant-negative construct
in the human glomerular mesangial celis. The Smad2 and Smad3 C-terminal
phosphorylation was flot affected by LY294002, whereas the total serine
phosphorylatiori was decreased. The transcriptional activity of Smad3 mutated at
C-terminal site was inhibited by LY294002, suggesting that activation of Smad3
by the PI3K pathway is flot dependent on the TGF-3 receptor I phosphorylation
target sites. The inhibition of PI3K pathway decreased the total serine
phosphorylation of Smad2/Smad3 as well as ifie association between
Smad2/Smad3 and Smad4, indicating the contributory role of PI3K pathway in the
formation of complex between Smad2/$mad3 and Smad4 (252). In a mammary
epithelial celi une, LY294002 decreased the Smad2 C-terminal phosphorylation
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suggesting the involvement of PI3K pathway in TGF--mediated phosphorylation
ofSmad2 (214).
The MAPK pathway inhibitors, PD98059 and U0126 also decreased the TGffl
induced total serine phosphorylation of Smad2/3 without affecting the
phosphorylation in its C-terminal region in human mesangial ceils (253). There
might be some regulatory role of ERK pathway on Smad pathway. PI3K has been
shown to activate ERK in certain celi types (211,212), so the phosphorylation of
Smad2/3 by PI3K in response to TGF-3 could be mediated by ERK. It seems that
MAPK and Smad pathways are directly invôlved in the TGF-(3-induced expression
of TflvJP-3 protein. Interactions of these pathways will be the subject of future
research.
The experiments with inhibitors, sense and antisence RNA and siRNAs have
certain limitations. The use of higher concentrations can cause some toxic and non
specific effects. However, the concentrations of these reagents used in our
experimentation are non-toxic under our experimental conditions. Methyl thiazole
tetrazolium (MTT) viability assay for the PI3K inhibitors and siRNA has shown
that the percentage decrease in chondrocytes viability is iess than 7% of the control
value, which is non significant (data flot shown). Secondly, alter harvesting, equal
amount of RNA and protein was loaded for analysis, 50 ciearly the decrease in the
mRNA and protein was due to particular inhibiting agent. Additionally, internai
control RNAs (28S) or proteins (total respective proteins or i3-actin) leveis were
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flot affected. In many cases, negative controls of pharmacological inhibitors or
siRNAs were used to demonstrate the specific effects.
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Conclusions and future perspectives
In summary, based on our resuits, we propose that TGF-3 exerts its growth
promoting effects on chondrocytes by activating ERK-MAPK, PI3K!AKT and
Smad pathways, which in tum could increase Spi activity and the formation of
Smad complex, which binds to the DNA leading to T]MP-3 induction.
Overexpression ofTIMP-3 in response to TGF-3 and versatile ability ofTIMP-3 to
inhibit cartilage-degrading MMPs, ADAMTS and TNF-a-activating, ADAM- 17
gives it a therapeutic value for arthritis. TIIvJP-3 binding to heparan sulfate and
chondroitin sulfate may result in strengthening of cartilage ECM, increased
chondrocyte viability and maintenance ofj oint tissue integrity. It is also interesting
to note that in contrast with the ceil proliferation and survival-associated PI3KŒ
and isoforms, Imockout and specific pharmacological inhibition of PI3Ky
isoform lias recently been shown to reduce both synovial inflammation and
cartilage erosion in RA-like mouse models (254). Thus, specific isoforms of this
pathway have different functions and can be targeted for reducing inflammation or
enhancing survival. further, observed suppression of arthritic inflammation by
TGF-f3 could in part be due to increased TIIvTP-3 and reduced TACE and TNF-Œ
activities. Thus, a better understanding of the mechanisms of TflvIP-3 induction by
TGF-3 can lead to novel therapies for inhibiting synovial
hyperplasialinflammation and for stimulating cartilage regeneration, the two
important goals in treating arthritis. The TGF-$-induced ERK-MAPK, PI3KIAKT
and Smad pathways appear to be independent of one another. Nevertheless, based
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on the literature, there may be synergy and cross talk between these signalling
intermediates as the inhibition of any one of the pathways resuited in inhibition of
TUvIP-3 protein expression. Thus multiple pathways and their interactions are
responsible for the activation of TIMP-3 gene. Such studied wiii be the subject of
future research in the laboratory. The pharmacological inhibition and RNA
interference-mediated knockdown approaches showed that TGF-13 receptor
activated $mad2 and Smad3 and co-Smad4 are required for induction of TIMP-3
expression and promoter activity by TGF-t3. We have aiso identified a minimal
TIMP-3 promoter fragment needed for this TGF-13 response. Thus TIMP-3 is a
target of the Smad pathway. These signaling cascades invoived in TGf-f3 induced
TINP-3 expression may have a pivotai role in cartilage ECM synthesis, repair and
maintenance.
One question of future interest is the order of activation and possible interaction of
these pathways, which need additional work. The future work wiil also be focused
on the nature of interaction of Smad and Spi with TEVIP-3 promoter DNA. Our
initial ChIP anaiysis has shown that Smad2, Smad4 and Spi bind directly in the
general TJMP-3 promoter region. One possibility is that Smad2/4 compiex bind
directly with SBEs in the TIMP-3 promoter region or may interact with Spi to
activate TIMP-3 promoter. Whether Spi and $mad bind directiy to each other or
through a third partner, like some activating proteins stili remains to be answered
in chondrocytes. Future studies on detailed protein-DNA interactions and
composition of SmadJSpl transcriptional complex wili generate more precise
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molecular mechanisms involved in TGF-3-induced TIMP-3 gene expression. This
may require additional mutants and in vitro mutagenesis of specific motifs. Our
studies also do flot rule out the involvement of additional pathways and
transcription factors in TGF-(3-regulated TIMP-3.
TGf-$ has a major role in chondrogenesis during development and the growth of
aduit chondrocytes, but based on our study, its effects on matrix production and
stability appears to be more pronounced. The term growth is generally used in the
context of increase in the number of celis by means of celi division. In our study
we have treated the serum-starved chondrocytes with TGF-f for 24 hours and this
short treatment did flot resuit in any increase in the number of celis. Analysis by
MIT ceil proliferation assay, for the viability of the celis, has flot shown any
significant increase or decrease in the number of ceils (data flot shown). TGF-j3
induces certain metabolic responses but alone was unable to promote chondrocyte
proliferation in 24 hours time period. However, the long-terni treatment of TGf-t3
(one to two weeks) leads to proliferation, and when used in combination with other
growth factors resulted in enhanced proliferation. TGF-t3 and bFGf combination
resulted in 136-fold increase in ce!! number (255). On the other hand TGF-3 has
stimulatory effect on the expression of TIMP-3 protein, which is inhibitor of
cartilage-degrading MMPs, ADAMTS and TNF-Œ-activating, ADAM-1 7. In other
reports, TGF-3 induced three-fo!d increase in type II collagen expression in
chondrocytes in 24 hours (256), whereas the increased aggrecan expression was
observed just after three hours of treament of TGF-3 in chondrogenic ATDC5 celis
120
(200). Both collagen type II and aggrecan proteins are important components in the
structure of cartilage matrix; thus, we can speculate that the effect of TGF-3 may
be relafively more pronounced on mati-ix production and stability. In summary, we
have elucidated some of the early TGF-$ signaffing mechanisms leading to TIMP
3 induction.
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